Preparation method and application of antibody conjugated drug
Patent Information
- Application Number
- TW111116237
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-29
- Filing Date
- 2022-04-28
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-04-27
AI Technical Summary
Existing antibody-drug conjugates (ADCs) using camptothecin drugs face issues with stability, half-life attenuation, and toxic side effects, limiting their effectiveness and safety in tumor treatment, particularly for breast cancer with low HER2 expression.
A novel linker system is developed to conjugate highly hydrophobic anti-tumor drugs like exatecan and belotecan with antibodies, enhancing hydrophilicity and stability, reducing aggregation, and improving drug release, thereby increasing in vivo half-life and therapeutic window.
The novel linker system results in antibody-drug conjugates with improved stability, biological activity, and safety, enhancing anti-tumor activity and therapeutic efficacy.
Smart Images

Figure TWG2TB001919948_001 
Figure TWG2TB001919948_002 
Figure TWG2TB001919948_003
Abstract
Description
Technical Field
[0001] This disclosure pertains to the field of biomedicine, specifically to the preparation method and application of an antibody-drug conjugate. Prior Technology
[0002] As a novel targeted therapy, antibody-drug conjugates (ADCs) deliver drugs to the disease site via appropriate carriers. However, due to limitations in antibody and highly active cytotoxic drug technology, a limited number of ADCs have been approved for marketing, and their application in cancer treatment urgently needs rapid development.
[0003] Cytotoxic agents are essential for the efficacy of ADC drugs, and camptothecin-based drugs show great promise. Marketed ADC drugs Trodelvy and Enhertu utilize camptothecin-based drugs SN38 and DX-8951f as their warhead molecules, respectively. However, ADCs prepared using camptothecin-based drugs significantly alter the properties of monoclonal antibodies, resulting in substantial reductions in stability and half-life. Although Enhertu achieved a confirmed objective response rate (ORR) of 79.7% in the DESTINY-Breast03 clinical trial, the DS8201-A-J101 clinical trial showed that for HER2-low expression breast cancer, Enhertu's confirmed ORR was only 37.0%, significantly lower than that for high or moderately expressed breast cancer. Furthermore, new symptoms of ADC drug toxicity have emerged, such as pneumonia and interstitial lung disease associated with Enhertu. WO 2020233174 A1 discloses a class of camptothecin compounds containing a valine-citrulline (Val-Cit)-PAB linker; however, this molecule cannot be conjugated with an antibody to obtain a qualified antibody-drug conjugate (ADC) molecule (the polymer content in a qualified ADC product needs to be less than 5%). Therefore, there is an urgent need in the art to provide more suitable antibody-drug conjugates based on camptothecin drugs (such as ethanotecan, beloteccan, etc.) to achieve efficient, simple, and practical chemical preparation and conjugation, and to improve the pharmaceutical properties, metabolic properties, efficacy, and safety of existing antibody-drug conjugates, such as improving ADC molecule stability and increasing the therapeutic window. Summary of the Invention
[0004] This disclosure provides an antibody-drug conjugate (ADC), its intermediate, preparation method, and applications. The ADC disclosed here enables the widespread application of cytotoxic drugs in the ADC field for the treatment of tumor diseases. The main technical advantages of this disclosure are: the novel linker provided allows for the conjugation of highly hydrophobic antitumor drugs, such as topoisomerase inhibitors ixanotecan and beloteccan, to antibodies via specific chemical methods. The resulting conjugate exhibits high hydrophilicity and stability. Compared to traditional ADC linkers, the linker provided here is less prone to antibody-drug aggregation at higher drug loading levels. Furthermore, compared to similar ADC drugs, the toxin molecules released in this disclosure are the original molecules of the topoisomerase inhibitors ixanotecan and beloteccan. Tests show that these drug molecules have better biological activity, safety, and other drug-related properties than the drug derivatives released by similar ADC drugs. Therefore, this disclosure can increase the drug's in vivo half-life and concentration in tumor tissues, thereby enhancing the drug's antitumor activity and / or improving the overall therapeutic window.
[0005] On the one hand, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound comprises the structure shown in formula (C-Trop-2): Q1 includes a connector. L1 contains -L1a-C(=O)-, Wherein, L1a is selected from the following group: alkylene groups to be substituted, polyethylene glycol groups to be substituted, alkenyl groups to be substituted, ynylene groups to be substituted, alicyclic groups to be substituted, heterocyclic groups to be substituted, aryl groups to be substituted, and heteroaryl groups to be substituted; L2 contains peptide residues that need to be substituted. L3 contains spacer groups that can be substituted as needed. Wherein, L2 and / or L3 contain polyinosine residues that need to be substituted. T contains drug units. Ab represents the ligand that can bind to Trop-2, and m is a number from 1 to 8.
[0006] On the other hand, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof. The compound comprises a structure selected from the group consisting of: and Ab represents the ligand that can bind to Trop-2, and m is a number from 1 to 8.
[0007] On the other hand, this disclosure provides a pharmaceutical composition comprising any of the compounds described in this disclosure, or tautomers, meso compounds, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, prodrugs, or solvates thereof, and, where appropriate, a pharmaceutically acceptable carrier.
[0008] On the other hand, this disclosure provides the use of compounds, or tautomers, meso compounds, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, prodrugs, or solvates thereof, and / or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment and / or prevention of tumors.
[0009] On the other hand, this disclosure provides an antibody-drug conjugate formed by conjugating an antibody with a compound disclosed herein.
[0010] In one embodiment, the conjugate disclosed herein is covalently linked to one or more pharmaceutical components.
[0011] In one embodiment, the antibody and drug disclosed herein are coupled by covalent means (e.g., by covalently linking them to a linker respectively).
[0012] On the other hand, this disclosure provides a method for preparing an antibody-drug conjugate, which involves reducing the disulfide chain in the hinge region of the antibody or antibody fragment to generate a pair of cysteine residues, and then subjecting the thiol group in the cysteine residues to a substitution reaction with the linking group of the compound disclosed herein, such as a maleic anhydride group, thereby linking the compound disclosed herein to the cysteine thiol group of the antibody or antibody fragment to obtain an antibody-drug conjugate. The drug-antibody conjugation ratio DAR (e.g., m in this disclosure) is controlled according to the reaction conditions, for example, it is commonly between 2 and 8.
[0013] On the other hand, in this disclosure, m represents the molar ratio of cytotoxic drug molecules to antibodies (also known as DAR, i.e., drug-antibody conjugation ratio). m can be an integer or a decimal. It can be understood as the average molar ratio of drug molecules to monoclonal antibody molecules in the antibody-drug conjugate obtained after conjugating a single monoclonal antibody molecule with a cytotoxic drug. It can generally be determined by hydrophobic-interaction chromatography (HIC), reverse phase HPLC (RP-HPLC), polyacrylamide-SDS gel electrophoresis (SDS PAGE), liquid chromatography-mass spectrometry (LC-MS), ultraviolet / visible spectroscopy (UV / Vis), etc.
[0014] On the other hand, this disclosure provides a method for preparing the disclosed compound, which includes the following steps:
[0015] An active ester of an amino acid with an amino protecting group N1 is contacted with an amino acid to obtain intermediate M1; intermediate M1 is contacted with substituted / unsubstituted p-aminobenzyl alcohol in the presence of a condensing agent such as EEDQ (2-ethoxy-1-ethoxycarbazo-1,2-dihydroquinoline) to obtain intermediate M2; the N1 of intermediate M2 is removed to obtain intermediate M3; intermediate M3 is contacted with a compound containing a mariamine group to obtain intermediate M4; intermediate M4 is contacted with bis(4-nitrophenyl) carbonate to obtain intermediate M5; and intermediate M5 is contacted with a pharmaceutical unit.
[0016] In one embodiment, the N1 comprises a fluorenylmethoxycarbonyl group.
[0017] In one embodiment, when preparing the compound in which the L2 is replaced by a structure containing polysinolytic acid residues, an intermediate containing an amino protecting group N2 is contacted with trifluoroacetic acid and then with acetylated polysinolytic acid.
[0018] In one embodiment, the N2 comprises a third butoxycarbonyl group.
[0019] On the other hand, this disclosure provides a method for preparing the disclosed compound, comprising the step of contacting the ligand with the disclosed compound under conditions suitable for forming a bond between the ligand and the compound.
[0020] In one embodiment, the ligand is contacted with the disclosed compound in a mixture of buffer solution and organic solvent.
[0021] In one embodiment, the ligand is contacted with the compound disclosed herein at a temperature of about 0 to about 37°C.
[0022] In one embodiment, the step of contacting the ligand with the disclosed compound includes: reacting the ligand with a reducing agent in a buffer solution to obtain the reduced ligand.
[0023] In one embodiment, after obtaining the reduced ligand and before contacting the ligand with the disclosed compound, the step of removing the reducing agent is included.
[0024] In one embodiment, removing the reducing agent comprises subjecting the reaction product to desalination column and / or ultrafiltration.
[0025] In one embodiment, the reducing agent is selected from the group consisting of tris(2-carboxyethyl)phosphine hydrochloride (TCEP), beta-mercaptoethanol, beta-mercaptoethylamine hydrochloride, and dithiothreitol (DTT).
[0026] In one embodiment, the buffer is selected from the group consisting of: potassium dihydrogen phosphate-sodium hydroxide (KH2PO4-NaOH) / sodium chloride (NaCl) / diethyltriaminepentaacetic acid (DTPA) buffer, disodium hydrogen phosphate-citric acid / sodium chloride (NaCl) / diethyltriaminepentaacetic acid (DTPA), boric acid-borax / sodium chloride (NaCl) / diethyltriaminepentaacetic acid (DTPA), histidine-sodium hydroxide / sodium chloride (NaCl) / diethyltriaminepentaacetic acid (DTPA) and PBS / diethyltriaminepentaacetic acid (DTPA).
[0027] In one embodiment, the organic solvent is selected from the group consisting of acetonitrile (ACN), dimethylformamide (DMF), dimethylacetamide (DMA), and dimethyl sulfoxide (DMSO).
[0028] In one embodiment, the organic solvent accounts for no more than 30% of the volume of the mixture of buffer solution and organic solvent.
[0029] This disclosure reveals that, compared to traditional antibody-drug conjugates, the antibody-drug conjugates presented here exhibit greater stability and are less prone to polymerization due to the excessive hydrophobicity of ethanotec and belotecamine-like drugs, and the introduction of polyinosinic acid significantly increases the hydrophilicity of the conjugates. Furthermore, this disclosure provides carbamate esters that undergo rapid 1,6-elimination after enzymatic cleavage to release the drug, exhibiting better in vitro and in vivo stability and bioactivity. Based on these findings, this disclosure was completed.
[0030] Other aspects and advantages of this disclosure will be readily apparent to those skilled in the art from the following detailed description. Only exemplary embodiments of this disclosure are shown and described in the following detailed description. As will be recognized by those skilled in the art, the content of this disclosure enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention to which this disclosure pertains. Accordingly, the drawings and descriptions in the specification of this disclosure are merely exemplary and not restrictive. Simple Explanation of the Diagram
[0031] The specific features of the invention disclosed herein are shown in the appended claims. The features and advantages of the invention disclosed herein can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows: Figure 1 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 1 disclosed herein; Figure 2 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 2 disclosed herein; Figure 3 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 2 disclosed in this paper; Figure 4 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 3 disclosed herein; Figure 5 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 4 disclosed herein; Figure 6 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 4 disclosed in this paper; Figure 7 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 5 disclosed herein; Figure 8 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 5 disclosed in this paper; Figure 9 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 6 disclosed herein; Figure 10 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 6 disclosed herein; Figure 11 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 7 disclosed herein; Figure 12 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 7 disclosed herein; Figure 13 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 8 disclosed herein; Figure 14 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 8 disclosed herein; Figure 15 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody-drug conjugate 9 disclosed herein; Figure 16 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 9 disclosed herein; Figure 17 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 10 disclosed herein; Figure 18 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 10 disclosed herein; Figure 19 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 11 disclosed herein; Figure 20 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 11 disclosed herein; Figure 21 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 12 disclosed herein; Figure 22 shows the high-performance liquid chromatography (HIC-HPLC) chromatogram of the hydrophobic interaction of antibody conjugate 12 disclosed herein; Figure 23 shows the concentration changes in the accelerated stability test of some of the antibody conjugates disclosed in this paper; Figure 24 shows the accelerated stability experiment of the antibody conjugates disclosed in this paper, illustrating the increase in polymer content. Figure 25 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 13 disclosed herein; Figure 26 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 14 disclosed herein; Figure 27 shows the size exclusion chromatography (SEC-HPLC) chromatogram of antibody conjugate 15 disclosed herein; Figure 28 shows a comparison of the efficacy of some of the antibody-drug conjugates disclosed in this study in human lung squamous cell carcinoma NCI-H2170 cells. Figure 29 shows the changes in mouse body weight during the in vivo efficacy experiment of the antibody-drug conjugate disclosed herein in human lung squamous cell carcinoma NCI-H2170. Implementation
[0032] The following specific embodiments illustrate the implementation of the invention disclosed herein. Those skilled in the art can easily understand other advantages and effects of the invention disclosed herein from the content disclosed in this specification.
[0033] [Terminology Definition] In this disclosure, the term "ligand" generally refers to a macromolecular compound that recognizes and binds to antigens or receptors associated with target cells. The role of a ligand can be to present a drug to a target cell population that has bound to it. These ligands include, but are not limited to, protein hormones, lectins, growth factors, antibodies, or other molecules that can bind to cells, receptors, and / or antigens. In this disclosure, a ligand can be represented as Ab. The ligand antigen forms a linker bond between a heteroatom on the ligand and a linker unit. It can be an antibody or its antigen-binding fragment, and the antibody can be selected from chimeric antibodies, humanized antibodies, fully human antibodies, or murine antibodies; the antibody can be a monoclonal antibody. For example, the antibody can be an antibody or its antigen-binding fragment targeting a site selected from the group consisting of HER2.
[0034] In this disclosure, the term "alkyl" generally refers to a residue derived from an alkane by removing a hydrogen atom. Alkyl groups can be substituted or unsubstituted, substituted or non-substituted. The term "alkyl" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having residues derived from the removal of hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane, and can be a straight-chain or branched group containing 1 to 20 carbon atoms, for example, containing 1 to 12 carbon atoms, such as a chain alkyl containing 1 to 6 carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, etc. Alkyl groups can be substituted or unsubstituted, alternative or non-alternative. For example, when substituted, the substituent can be substituted at any usable connection point. The substituent can be independently selected as needed from one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamine, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and lateral oxy groups. For example, it can be hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or C1-6 aliphatic groups.
[0035] In this disclosure, the term "alkylene" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane. It can be a straight-chain or branched group containing 1 to 20 carbon atoms. For example, the term "methylene" can refer to a residue derived from the removal of two hydrogen atoms from a 1-carbon group. The methylene group can be substituted or unsubstituted, substituted or non-substituted; for example, containing 1 to 12 carbon atoms, such as an alkylene group containing 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-). The alkylene group can be substituted or unsubstituted, alternative or non-alternative. For example, when substituted, the substituent can be replaced at any usable connection point. The substituent can be independently selected as needed from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamine, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, and lateral alkyl groups. One or more substituents may be present, such as hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or a C1-6 aliphatic group. The methylene or alkylene group may be substituted or unsubstituted.
[0036] In this disclosure, the term "alkenyl" generally refers to a straight-chain or branched hydrocarbon group containing one or more double bonds. Exemplary examples of alkenyl groups include allyl, homoallyl, vinyl, crotonyl, butenyl, pentenyl, and hexenyl. Exemplary examples of C2-6 chain alkenyl groups having more than one double bond include butadienyl, pentadienyl, hexadienyl, and hextrienyl, as well as their branched forms. The unsaturated bond (double bond) can be located at any position on the carbon chain. Alkenyl groups can be substituted or unsubstituted.
[0037] In this disclosure, the term "alkenyl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkene. For example, it can be allyl, vinyl, butenyl, pentenyl, and hexenyl, etc. The alkenyl group can be substituted or unsubstituted.
[0038] In this disclosure, the term "alkynyl" generally refers to an unsaturated straight-chain or branched alkynyl group, such as ethynyl, 1-propynyl, propynyl, butynyl, etc. Alynyl groups can be substituted or unsubstituted.
[0039] In this disclosure, the term "ethynyl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkyne. For example, it can be ethynyl, propynyl, propynyl, butynyl, etc. The ethynyl group can be substituted or unsubstituted.
[0040] In this disclosure, the term "aryl" generally refers to a residue derived from the removal of a hydrogen atom from an aromatic ring. The term "aromatic ring" can refer to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) having a conjugated π-electron system, and can be 6 to 10 members, such as benzene and naphthalene. The aromatic ring can be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring. The aryl group can be substituted or unsubstituted, and when substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio. The aryl group can be substituted or unsubstituted.
[0041] In this disclosure, the term "aryl" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an aromatic ring. For example, it could be phenylene or naphthylene. The aryl group can be substituted or unsubstituted.
[0042] In this disclosure, the term "heteroaryl" generally refers to a residue derived from the removal of a hydrogen atom from a carbon atom of a heteroaryl ring. The term "heteroaryl ring" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. The heteroaryl group can be 5 to 10 members, or 5 or 6 members, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is the heteroaryl ring. Heteroaryl groups can be substituted or unsubstituted as desired. When substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. Heteroaryl groups can be substituted or unsubstituted.
[0043] In this disclosure, the term "hybrid aryl" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of a heteroaryl ring. Examples include hybrid furanyl, hybrid thiopheneyl, hybrid pyridinyl, hybrid pyrroleyl, hybrid pyrimidinyl, hybrid pyrazinyl, hybrid imidazolyl, hybrid tetrazolyl, etc. Hybrid aryl groups can be substituted or unsubstituted.
[0044] In this disclosure, the term "alicyclic group" generally refers to a residue derived by removing a hydrogen atom from the same carbon atom or multiple different carbon atoms of an aliphatic ring. The term "cycloalkane" generally refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon containing 3 to 20 carbon atoms, 3 to 12 carbon atoms, 3 to 10 carbon atoms, or 3 to 8 carbon atoms. Non-limiting examples of alicyclic groups include cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptanetrienyl, cyclooctane, etc.; polycyclic carbocyclic rings may include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. Alicyclic groups can be substituted or unsubstituted. In this disclosure, the term "carbocyclic group" generally refers to a residue derived by removing a hydrogen atom from a carbon atom of a carbocyclic ring. The term "carbocyclic ring" generally refers to saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbons containing 3 to 20 carbon atoms, 3 to 12 carbon atoms, 3 to 10 carbon atoms, or 3 to 8 carbon atoms. Non-limiting examples of monocyclic carbocyclic rings include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptanetriene, cyclooctane, etc.; polycyclic carbocyclic rings can include spirocyclic, fused, and bridged rings. The carbocyclic group can be substituted or unsubstituted. In some cases, alicyclic and carbocyclic rings can be used interchangeably.
[0045] In this disclosure, the term "partially unsaturated" generally refers to a cyclic structure in which the cyclic molecules contain at least one double or triple bond. The term "partially unsaturated" encompasses cyclic structures with multiple unsaturations, but is not intended to include aromatic or heteroaromatic rings as defined in this disclosure. The term "unsaturated" indicates that a portion has one or more degrees of unsaturation.
[0046] In this disclosure, the term "alicyclic group" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an alicyclic ring. For example, it can be cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptanetrienyl, cyclooctane, etc.; the polycyclic carbocyclic ring can include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. The alicyclic group can be substituted or unsubstituted.
[0047] In this disclosure, the term "aliphatic heterocyclic group" generally refers to a stable, non-aromatic 3-7 member monocyclic carbocyclic structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. These cyclic structures can be saturated or partially saturated and contain one or more heteroatoms in addition to carbon atoms. These heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it may contain 1-4 heteroatoms as defined above. When used to refer to atoms in an aliphatic heterocyclic structure, the term "nitrogen" can include nitrogen that has undergone a substitution reaction. For example, an aliphatic heterocyclic group can include "heterocyclic alkyl," which can refer to a stable, non-aromatic 3-7 member monocyclic alkyl structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. In addition to carbon atoms, these cyclic structures contain one or more heteroatoms in addition to carbon atoms. These heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it may contain 1-4 heteroatoms as defined above. Heterocyclic alkyl groups can be substituted or unsubstituted. Alicyclic groups can be substituted or unsubstituted.
[0048] In this disclosure, the term "allelic heterocyclic group" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alicyclic ring. Allelic heterocyclic groups can be substituted or unsubstituted.
[0049] In this disclosure, the terms “as needed” or “as needed” generally refer to an event or circumstance described subsequently that may but does not necessarily occur, and the description includes situations in which the event or circumstance occurs or does not occur. For example, “heterocyclic groups substituted with alkyl groups as needed” means that alkyl groups may but do not necessarily be present, and the description can include cases where heterocyclic groups are substituted with alkyl groups and cases where heterocyclic groups are not substituted with alkyl groups.
[0050] In this disclosure, the term "substituted" generally refers to one or more hydrogen atoms in a group, for example, up to five, or for example, one to three hydrogen atoms, independently substituted by the corresponding number of substituents. The substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) the possible or impossible substitutions without much effort. For example, an amino group or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).
[0051] In this disclosure, as is known to those skilled in the art, terms such as "alkyl," "alkenyl," and "cycloalkyl" may be preceded by an identifier indicating the number of atoms present in the group under specific conditions, for example, C1-C4 alkyl, C3-C7 cycloalkoxy, C1-C4 alkylcarbonylamine, etc., with the subscript number following "C" indicating the number of carbon atoms present in the group. For example, C3 alkyl refers to an alkyl group having three carbon atoms (e.g., n-propyl, isopropyl); in C1-10, members of the group may have any number of carbon atoms falling within the range of 1-10.
[0052] One or more hydrogen atoms in a group, for example, up to five, or for example, one to three hydrogen atoms, are independently replaced by the corresponding number of substituents. The substituents are only in their possible chemical positions, and those with ordinary knowledge in the art can determine (by experiment or theory) the possible or impossible substitutions without much effort. For example, an amino group or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).
[0053] In this disclosure, the term "compound" generally refers to a substance having two or more different elements. For example, the compounds disclosed herein can be organic compounds, compounds with a molecular weight of less than 500, less than 1000, more than 1000, or more than 10,000 or 100,000. In this disclosure, a compound can also refer to a compound linked by chemical bonds. For example, it can be a compound in which one or more molecules with a molecular weight of less than 1000 are linked by chemical bonds to a biological macromolecule, such as a polysaccharide, protein, nucleic acid, polypeptide, etc. For example, the compounds disclosed herein can include compounds in which a protein is linked to one or more molecules with a molecular weight of less than 1000, compounds in which a protein is linked to one or more molecules with a molecular weight of less than 10,000, or compounds in which a protein is linked to one or more molecules with a molecular weight of less than 100,000.
[0054] In this disclosure, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements. The terms "above" and "below" generally refer to situations that include the stated number.
[0055] In this disclosure, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0056] In this disclosure, the compounds disclosed include their tautomers, meso compounds, racemates, enantiomers, and / or diastereomers. In this disclosure, the term "diastereomer" generally refers to a stereoisomer having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers can have different physical properties, such as melting point, boiling point, spectral properties, and reactivity. In this disclosure, the terms "tautomer" or "tautomer form" are used interchangeably and generally refer to structural isomers of different energies that can be interconverted by a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by the rearrangement of some bonding electrons. In this disclosure, the term "meta-form" generally refers to a molecule containing asymmetric atoms but possessing symmetry factors that result in zero total optical rotation within the molecule. The terms "racemic form" or "racemic mixture" refer to a composition consisting of two enantiomers in equal molar amounts.
[0057] In this disclosure, certain atoms of the disclosed compounds may occur in more than one isotopic form. For example, hydrogen may exist as protium (¹H), deuterium (²H), and tritium (³H), and carbon may occur naturally in three different isotopes (¹²C, ¹³C, and ¹⁴C). Examples of isotopes that may be incorporated into the disclosed compounds include, but are not limited to, ¹⁵N, ¹⁸O, ¹⁷O, ¹⁸F, ³²P, ³³P, ¹²⁹I, ¹³¹I, ¹²³I, ¹²⁴I, ¹²⁵I, or similar isotopes. Thus, the disclosed compounds may be enriched in one or more of these isotopes relative to their natural abundance. As is known to those skilled in the art, such isotope-enriched compounds can be used for a variety of purposes. For example, substitution with a heavy isotope such as deuterium (²H) may provide certain therapeutic advantages, which could be due to greater metabolic stability. For example, the natural abundance of deuterium (²H) is approximately 0.015%. Therefore, there is approximately one deuterium atom for every 6500 hydrogen atoms in nature. Consequently, the deuterium-containing compounds disclosed herein have a deuterium abundance greater than 0.015% at one or more positions (as the case may be). Unless otherwise specified, the structures described herein may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, compounds whose structures are otherwise identical to those disclosed herein, except that hydrogen atoms are replaced by deuterium or tritium, or carbon atoms are replaced by carbon-13 or carbon-14, are within the scope of this disclosure.
[0058] In this disclosure, the term "pharmaceutical composition" generally refers to a mixture containing one or more of the compounds described in this disclosure or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. Pharmaceutical compositions can facilitate drug delivery to organisms, enhance the absorption of the active ingredient, and thereby exert its biological activity. Conventional preparation methods for pharmaceutical compositions are described using techniques commonly employed in the art.
[0059] In this disclosure, the terms "pharmaceutically acceptable salt" or "medicinal salt" generally refer to salts of the compounds or ligand-drug conjugates disclosed herein, or salts of the compounds described herein, which are safe and / or effective when used in mammals and have the desired biological activity. The antibody-antibody-drug conjugates disclosed herein can form salts with acids. Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogen sulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, or p-toluenesulfonate.
[0060] In this disclosure, the term "coupled compound" generally refers to a compound prepared by one or more chemical reactions, or a compound connected to each other by one or more connecting structures such as bridges, spacers, or connecting parts.
[0061] In this disclosure, the term "pharmaceutically acceptable carrier" generally refers to a carrier for administering therapeutic agents, such as antibodies or peptides, genes, and other therapeutic agents. This term refers to any pharmaceutical carrier that does not itself induce antibody production harmful to the individual receiving the composition and can be administered without causing excessive toxicity. For example, a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used in genetic engineering to contain a target gene. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates, and inactivated viral particles. These carriers are well known to those skilled in the art. Pharmaceutically acceptable carriers in therapeutic compositions may include liquids such as water, saline, glycerol, and ethanol. These carriers may also contain auxiliary substances such as wetting agents or emulsifiers, pH buffers, etc.
[0062] In this disclosure, the terms "Trop2" and "TROP2" generally refer to a single-pass transmembrane type I cell membrane protein. In this disclosure, the term "Trop2" may also encompass homologs, variants, and isoforms of Trop 2, including splice isoforms. The term "Trop" also includes proteins having one or more sequences from Trop 2 homologs, variants, and isoforms, as well as fragments of those sequences, provided they are variant proteins (including isoforms). Trop2 can be human Trop2. For example, Uniprot accession number P09758 provides a description of Trop2 and its sequence.
[0063] In this disclosure, the term "HER2" generally refers to human epidermal growth factor receptor 2 (HER2). For example, the term "HER2" refers to any naturally occurring HER2 from any human source. The term also encompasses "full-length" and unprocessed HER2, as well as any form of HER2 derived from cells and processed (e.g., mature protein). The term also covers naturally occurring variants and isotypes of HER2, such as splice variants or allelic variants. For example, Uniprot accession number P04626 provides a description of HER2 and its sequence.
[0064] In this disclosure, the term “Nectin-4” generally refers to adhesion molecule 4. For example, the term “Nectin-4” refers to any naturally occurring Nectin-4 from any human source. The term also covers “full-length” and unprocessed Nectin-4, as well as any form of Nectin-4 derived from cells and processed (e.g., mature protein). The term also covers naturally occurring variants and isotypes of Nectin-4, such as splice variants or allelic variants. For example, Uniprot accession number Q96NY8 provides a description of Nectin-4 and its sequence.
[0065] In this disclosure, the term "chimeric antibody" generally refers to an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody, which can alleviate the immune response induced by murine antibodies. To establish a chimeric antibody, a fusion tumor secreting murine-specific monoclonal antibodies can be created. The variable region gene can then be selected from the murine fusion tumor cells, and the constant region gene of the human antibody can be selected as needed. The murine variable region gene and the human constant region gene are linked to form a chimeric gene, which is then inserted into an expression vector. The chimeric antibody molecule can then be expressed in eukaryotic or prokaryotic systems.
[0066] In this disclosure, the term "humanized antibody," also known as a CDR-grafted antibody, generally refers to an antibody generated by grafting a mouse CDR sequence into a human antibody variable region framework, i.e., an antibody within a different type of human germline antibody framework sequence. This can overcome the heterologous response induced by chimeric antibodies carrying a large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases containing germline antibody gene sequences or from publicly available references. For example, germline DNA sequences of human heavy and light chain variable region genes can be found in the VBase human germline sequence database.
[0067] In this disclosure, the terms "fully human antibody," "fully human antibody," or "completely human antibody," also known as "fully human monoclonal antibody," refer to antibodies whose variable and constant regions can both be human-derived, thus eliminating immunogenicity and toxic side effects. The development of monoclonal antibodies has gone through four stages: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies, and fully human monoclonal antibodies. The antibodies or ligands described in this disclosure can be fully human monoclonal antibodies. Related technologies for the preparation of fully human antibodies include: human fusion tumor technology, EBV-transformed B lymphocyte technology, phage display technology, transgenic mouse antibody preparation technology, and single B cell antibody preparation technology, etc.
[0068] In this disclosure, the term "CDR" generally refers to one of the six hypervariable regions within the variable domain of an antibody that primarily facilitate antigen binding. One of the most commonly used definitions of these six CDRs is provided by Kabat EA et al., Chothia et al., and MacCallum et al. As used in this disclosure, the Kabat definition of CDR can be applied to CDR1, CDR2, and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domain, and to CDR1, CDR2, and CDR3 (CDR H1, CDR H2, CDR H3 or H1, H2, H3) of the heavy chain variable domain.
[0069] In this disclosure, the term "group capable of coupling with a thiol" generally refers to the fact that compound A has a thiol group and compound B has a group capable of coupling with a thiol group. Compound B can achieve the connection between compound A and compound B by reacting the thiol group of compound A with the thiol group capable of coupling with a thiol group.
[0070] In this disclosure, the term "linker" generally refers to a chemical structural fragment or bond that is connected at one end to a group and at the other end to another group. It may also refer to the linker being connected to other linkers before being linked to a drug and / or ligand. The direct or indirect linker can refer to the group directly connecting the ligand via a covalent bond, or it can refer to the linker connecting the ligand via a linker. For example, the linker can be the structure shown in Q1 of this disclosure. For example, chemical structural fragments or bonds containing acid-labile linker structures (e.g., hydrazones), protease-sensitive (e.g., peptidase-sensitive) linker structures, light-labile linker structures, dimethyl linker structures, or disulfide-containing linker structures can be used as linkers.
[0071] In this disclosure, the term "linking group" generally refers to a group that has the ability to connect with another group. For example, a compound having a linking group can achieve the connection between the compound and another group through a coupling reaction between the linking group and another group. For example, the maleimine group can serve as a linking group.
[0072] In this disclosure, the term "pharmaceutical unit" generally refers to a chemical moiety that directly or indirectly conjugates an antibody or antigen-binding fragment to form an immunoconjugate. For example, a "pharmaceutical unit" includes, but is not limited to, compounds with antitumor activity described herein. For example, pharmaceutical units include topoisomerase inhibitors.
[0073] In this disclosure, the term "compound with antitumor activity" generally refers to a compound that has the ability to reduce the proliferation rate, viability, or metastatic activity of tumor cells. For example, antitumor activity may be demonstrated by a reduction in the growth rate of abnormal cells that appear during treatment, or by stabilization or shrinkage of tumor size, or by longer survival due to treatment compared to a control without treatment. Antitumor activity can be assessed using recognized in vitro or in vivo tumor models, such as xenograft models.
[0074] In some embodiments of the present invention, the bioactive molecule in the conjugate is a compound with specific antitumor activity, such as: radioactive isotopes, such as At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, or Lu; metal complexes, such as platinum complexes (e.g., oxaliplatin) or gold complexes; glycopeptide antibiotics, such as bleomycin or bleomycin; topoisomerase inhibitors; and drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, and gentamicin. Sitabine, mercaptopurine, pentostatin, fludarabine, cladribine, or nerabine, etc.; drugs acting on structural proteins, such as tubulin inhibitors (e.g., vinblastine, vincristine, paclitaxel, maytansine, aurestatin, tubulin B, or eribulin, etc.); tumor signaling pathway inhibitors, such as serine / threonine kinase inhibitors, tyrosine kinase inhibitors, aspartic acid kinase inhibitors, or histidine kinase inhibitors, etc.; proteasome inhibitors; epigenetic target inhibitors; tumor angiogenesis inhibitors; cell cycle protein inhibitors;
[0075] In this disclosure, the term "topoisomerase inhibitor" generally refers to compounds or derivatives thereof that include both topoisomerase I inhibitors and topoisomerase II inhibitors. Examples of topoisomerase I inhibitors include, but are not limited to, camptothecin and its analogues; and topoisomerase II inhibitors (such as actinomycin D, doxorubicin, doxorubicin, daunorubicin, mitoxantrone, podophyllotoxin, or etoposide). A topoisomerase can be an enzyme that corrects the number of rings in DNA by cleaving phosphodiester bonds in one or both strands and then rewinding and sealing them.
[0076] In this disclosure, the term "camptothecin analogue" generally refers to compounds that are structurally similar to or derived from camptothecin. For example, the structure of camptothecin can be described in CAS Registry No. 7689-03-4. Camptothecin analogues can refer to ixatecan (CAS Registry No. 171335-80-1) or beloteccan (CAS Registry No. 256411-32-2). The term "non-camptothecin topoisomerase I inhibitor" generally refers to heterocyclic molecules of the indolezoazole class, indomethacinone class, benzo[a]phenanthridine class, and dibenzonaphthidone class that possess topoisomerase I inhibitory activity, primarily referring to Genz-644282 (CAS Registry No. 529488-28-6).
[0077] In this disclosure, the term "disease associated with the expression of a target" generally refers to a disease in which the occurrence and / or progression of the disease is associated with the expression level of that target. For example, high expression means that the expression level of a target is increased in cells from a disease area, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, low expression means that the expression level of a target is decreased in cells from a disease area, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, positive expression means that cells from a disease area, such as a specific tissue or organ of a patient, express a target. Or, negative expression means that cells from a disease area, such as a specific tissue or organ of a patient, do not express a target. For example, the characteristics of target expression can be determined by standard assays known in the art.
[0078] In this disclosure, the term "effective amount" generally refers to the amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or the amount that exhibits a detectable therapeutic or preventative effect. The precise effective amount for a given subject depends on that subject's body size and health status, the nature and severity of the condition, and the choice of the therapeutic agent and / or combination of therapeutic agents administered. Therefore, it is useless to pre-specify an accurate effective amount. However, for a given condition, the effective amount can be determined using routine laboratory methods, and is readily apparent to the clinician.
[0079] Unless otherwise specified, all compounds mentioned in this disclosure are intended to include all possible optical isomers, such as compounds with a single chirality or mixtures of various chiral compounds (i.e., racemates). In all compounds disclosed herein, each chiral carbon atom may, as desired, be in the R configuration or the S configuration, or a mixture of the R and S configurations.
[0080] As used herein, the term "disclosed compound" refers to the compound disclosed herein. The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates, or solvates of the disclosed compound.
[0081] When a trade name is used in this document, it is intended to include the product formulation, its generic counterpart, and the active pharmaceutical ingredient of the product.
[0082] As used herein, "antibody" is used in its broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired biological activity. Antibodies can be mouse, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system capable of recognizing and binding to specific antigens. Target antigens generally have numerous binding sites, also called epitopes, recognized by the CDRs of various antibodies. Antibodies that specifically bind to different epitopes have different structures. Therefore, an antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or the immunoactive portion of full-length immunoglobulin molecules, i.e., molecules containing antigens or portions thereof that specifically bind to the target of interest, including, but not limited to, cancer cells or cells that produce autoantibodies associated with autoimmune diseases. The immunoglobulins described in this disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species. However, in one aspect, immunoglobulins are derived from humans, mice, or rabbits. An "antibody fragment" can comprise a portion of a full-length antibody, generally its antigen-binding region or variable region. Examples of antibody fragments include: Fab, Fab', F(ab')2, and Fv fragments; biantibodies; linear antibodies; minibody; fragments prepared from Fab expression libraries; anti-idiotypic (anti-Id) antibodies; CDR (complementarity-determining region); and any of the above epitope-binding fragments that bind to cancer cell antigens, viral antigens, or microbial antigens in an immune-specific manner; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The antibodies constituting antibody-drug conjugates in this disclosure can retain their original wild-state antigen-binding capacity. Therefore, the antibodies disclosed herein can, for example, specifically bind to antigens. The antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, cell survival regulators, cell proliferation regulators, molecules associated with tissue growth and differentiation (such as those known or anticipated to be functional), lymphokines, cytokines, molecules involved in cell circulation regulation, molecules involved in angiogenesis, and molecules associated with angiogenesis (such as those known to bind to antigens). Antigens that can be bound to antibodies may be one or a subset of the above categories, while other subsets may include other molecules / antigens with specific properties (compared to the target antigen). Antibodies used in antibody-drug conjugates include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens. Such tumor-associated antigens are well-known in the industry and can be prepared using well-known antibody preparation methods and information.These targets can be specifically expressed on the surface of one or more cancer cells, while being expressed sparingly or not at all on the surface of one or more non-cancer cells. Typically, such tumor-associated peptides can be overexpressed on the surface of cancer cells compared to their expression on non-cancer cells.
[0083] In this disclosure, the term "enfortumab" generally refers to an antibody targeting Nectin-4. For example, enfortumab may be described in WO2017042210A1. In this disclosure, enfortumab can refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of enfortumab.
[0084] In this disclosure, the term "pertuzumab" generally refers to an antibody targeting HER2. For example, pertuzumab can be described in WO2014172371A2. In this disclosure, pertuzumab can refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of pertuzumab.
[0085] In this disclosure, the term "trastuzumab" generally refers to an antibody targeting HER2. For example, trastuzumab can be described in US20060275305A1. In this disclosure, trastuzumab can refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of trastuzumab.
[0086] In this disclosure, the term "sacituzumab" generally refers to an antibody targeting TROP2. For example, sacituzumab (hRS7) can be described in WO2003074566. In this disclosure, sacituzumab can refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of sacituzumab.
[0087] In this disclosure, the term "patritumab" generally refers to an antibody targeting HER3. For example, paltratumab may be described in CN102174105B. In this disclosure, paltratumab can refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of paltratumab.
[0088] In this disclosure, the term "antibody H01L02" generally refers to an antibody targeting CDH6. For example, monoclonal antibody H01L02 may be described in WO2018212136 or US20200171163A1. For example, the H01L02 monoclonal antibody may be the monoclonal antibody used in the drug DS6000. In this disclosure, H01L02 monoclonal antibody may refer to any antibody or antigen-binding fragment containing the heavy chain variable regions CDR1-3 and light chain variable regions of the H01L02 monoclonal antibody.
[0089] In this disclosure, the term "peptide residue" generally refers to a residue consisting of one or more amino acid residues linked together. For example, one or more amino acids in a peptide residue may be substituted as desired. For example, the peptide residues disclosed herein may be selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamate-valine-alanine (Glu-Val-Ala), glutamate-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-aspartic acid (Ala-Ala-Asn), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).
[0090] In this disclosure, the term "polyethylene glycol group" generally refers to a residue consisting of one or more ethylene glycol residues linked together. For example, a polyethylene glycol group may contain -(CH2CH2O)p-, where p is a number that is at least 1. For example, the polyethylene glycol group in this disclosure may be substituted as needed.
[0091] In this disclosure, the term "glycol group" generally refers to a polyethylene glycol group. For example, the glycol group in this disclosure may be substituted as needed. For example, the number preceding the glycol group may indicate the number of ethylene glycol units in the glycol group; for example, a diethylene glycol group may refer to two ethylene glycol polymerized residues.
[0092] In this disclosure, the term "polyinosine residue" generally refers to a residue comprising one or more inosine residues linked together. For example, a polyinosine residue may contain -(COCH2N(CH3))q-, where q is a number at least 1. For example, the polyinosine residue in this disclosure may be substituted as needed. For example, a structure comprising a polyinosine residue may be... , where n2 is a number from 4 to 18.
[0093] In this disclosure, the term "sodium dodecyl sulfate polyacrylamide gel electrophoresis" generally refers to a material analysis and characterization technique. For example, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) can detect the molecular weight of a substance.
[0094] In this disclosure, the term "hydrophobic chromatography" generally refers to an analytical technique based on the differences in hydrophobicity between substances.
[0095] In this disclosure, the term "liquid chromatography-mass spectrometry" generally refers to an analytical method for identifying the components of a substance. For example, liquid chromatography-mass spectrometry can be used to analyze the molecular weight of an analyte by coupling liquid chromatography with mass spectrometry.
[0096] In this disclosure, the term "tumor" generally refers to any new pathological tissue proliferation. For the purposes of this disclosure, angiogenesis is part of the characteristics of a tumor. Tumors can be benign or malignant. The term "tumor" is generally used to refer to either benign or malignant tumors, while the term "cancer" is generally used to refer to malignant tumors, which can be metastatic or non-metastatic. Tumors that can be diagnosed using the methods disclosed herein are selected from the following groups: breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma, and mesothelioma. For research purposes, these tissues can be isolated from readily available resources using methods well known to those skilled in the art. [Detailed Description of the Invention]
[0097] On the one hand, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2): Q1 may include a connector. L1 can contain -L1a-C(=O)-, Wherein, L1a may be selected from the following group: alkylene groups to be substituted, polyethylene glycol groups to be substituted, alkenyl groups to be substituted, ynylene groups to be substituted, alicyclic groups to be substituted, heterocyclic groups to be substituted, aryl groups to be substituted, and heteroaryl groups to be substituted; L2 can contain peptide residues that need to be substituted. L3 may contain spacer groups that are substituted as needed; for example, the spacer groups disclosed herein may be capable of self-degradation. For example, the spacer groups disclosed herein may contain spacer groups that are substituted as needed. Or replace as needed .
[0098] Wherein, L2 and / or L3 may contain polyinosine residues that are substituted as needed. T can contain drug units. Ab can be a ligand that can bind to Trop-2, and m can be a number from 1 to 8.
[0099] On the other hand, this disclosure also provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2-M): Q1 may include a connector. L1 can contain -L1a-C(=O)-, Wherein, L1a may be selected from the following group: alkylene groups to be substituted, polyethylene glycol groups to be substituted, alkenyl groups to be substituted, ynylene groups to be substituted, alicyclic groups to be substituted, heterocyclic groups to be substituted, aryl groups to be substituted, and heteroaryl groups to be substituted; L2 can contain peptide residues that need to be substituted. L3 may contain spacer groups that are substituted as needed; for example, the spacer groups disclosed herein may be capable of self-degradation. For example, the spacer groups disclosed herein may contain spacer groups that are substituted as needed. Or replace as needed .
[0100] Wherein, L2 and / or L3 may contain structural unit -X, which may be replaced as needed. T can contain drug units. Ab can be a ligand that can bind to Trop-2, and m can be a number from 1 to 8.
[0101] For example, L3 is selected from the following group: [subject to replacement as needed] , and what needs to be replaced .
[0102] For example, the benzene ring of L3 can be substituted with a structural unit -X as desired. For example, the structural unit -X can be selected from the group consisting of: [details of the substituent]. X1 is selected from the group consisting of: carbonyl, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O, or S; X2 is selected from the group consisting of: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O, or S; X3 is selected from the group consisting of: Group: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O or S; wherein the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms are each independently and as needed substituted with one or more substituents selected from deuterated, halogenated, cyano, nitro, amino, alkyl, carboxyl, alkoxy or cycloalkyl.
[0103] For example, the benzene ring of L3 can be substituted with the desired structural unit -X. For example, the structural unit -X can contain the desired substituted... X1 is selected from the group consisting of: C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O or S, and each of the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms is independently and as needed selected from one or more substituents of deuterium, halogen, cyano, nitro, amino, alkyl, carboxyl, alkoxy or cycloalkyl.
[0104] For example, where structural unit -X is the one that needs to be replaced. .
[0105] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2-M2): Wherein, L may contain a substituted alkylene group, a substituted polyethylene glycol group, or a substituted alicyclic group, depending on the desired substitution; R1 may be an substituted isopropyl group or a substituted benzyl group, depending on the desired substitution; R2 may be a substituted methyl group, a substituted alicyclic group, or a substituted alkylene group, depending on the desired substitution. Or replace as needed R3 can be hydrogen or R5; where R5 can be substituted as needed. T may include ixanotecan (Exatecan, CAS Registry No. 171335-80-1) and / or belotecone (Belotecan, CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0106] For example, Q1 may contain a linker coupled with a thiol group.
[0107] For example, Q1 can be selected from the following group: (subject to replacement as needed) Replace as needed Replace as needed And what needs to be replaced .
[0108] For example, L1a may be selected from the group consisting of: C1-C7 alkylene groups to be substituted as needed, diethylene glycol to octaethylene glycol groups to be substituted as needed, C3-C6 alicyclic groups to be substituted as needed, aryl groups to be substituted as needed, and heteroaryl groups to be substituted as needed.
[0109] For example, L1a may be selected from the group consisting of: methylene, ethyl, propyl, butyl, pentyl, diethylene, tetraethylene, hexaethylene, octaethylene and cyclohexyl.
[0110] For example, L1a may be selected from the group consisting of methylene, ethyl, propyl, butyl, and pentyl.
[0111] For example, L1a may be selected from the group consisting of diethylene glycol group, triethylene glycol group, tetraethylene glycol group, pentaethylene glycol group, hexaethylene glycol group, heptaethylene glycol group, and octaethylene glycol group, depending on the need for substitution.
[0112] For example, L1a may be selected from the group consisting of: substituted cyclopropyl, substituted cyclobutyl and substituted cyclohexyl as desired.
[0113] For example, L2 may contain polypeptide residues consisting of amino acids selected from the group consisting of phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, aspartamine, glutamine, proline, citrulline, aspartic acid, and glycine.
[0114] For example, L2 may contain polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, aspartic acid, and lysine, which may be substituted as needed.
[0115] For example, L2 may contain polypeptide residues selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamate-valine-alanine (Glu-Val-Ala), glutamate-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-aspartic acid (Ala-Ala-Asn), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).
[0116] For example, L2 may contain polypeptide residues selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and valine-lysine (Val-Lys), which may be substituted as needed.
[0117] For example, when L2 contains a lysine residue, the lysine residue can be replaced by a structure R1 containing a polysine residue.
[0118] For example, any H contained in L2 can be replaced by R1.
[0119] For example, R1 can be replaced as needed. , where n1 is a number from 4 to 18, and R is selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy.
[0120] For example, n1 can be 4 to 18, 8 to 18, 4 to 12, or 8 to 12. For example, n1 can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
[0121] For example, L3 is selected from the following group: [subject to replacement as needed] , and what needs to be replaced .
[0122] For example, the benzene ring of L3 can be replaced by structure R2, which contains polyinosinic acid residues.
[0123] For example, any H in the benzene ring of L3 can be replaced by R2.
[0124] For example, in this case, the benzene ring of L3 is linked to the desired polyinosine residue via a structural unit -X-, which is selected from the group consisting of the desired polyinosine residue. X1 is selected from the group consisting of: carbonyl, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; X2 is selected from the group consisting of: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; and X3 is covalently bonded or selected from... The following group includes: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O, or S; wherein the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms are each independently and as desired substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, amino, alkyl, carboxyl, alkoxy, or cycloalkyl.
[0125] For example, the benzene ring of L3 is linked to polyinosine residues that require substitution via a structural unit -X-, which is selected from, but not limited to: , X1 is selected from the group consisting of: C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O or S, and each of the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms is independently and as needed selected from one or more substituents of deuterium, halogen, cyano, nitro, amino, alkyl, carboxyl, alkoxy or cycloalkyl.
[0126] For example, where the structural unit -X- is to be replaced as needed. The polyinosine residues that need to be replaced include , where n2 is a number from 4 to 18, and R is selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy.
[0127] For example, the structural unit -X- is selected from the following group: depending on the need for replacement. X1 is selected from the group consisting of: carbonyl, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; X2 is selected from the group consisting of: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; and X3 is covalently bonded or selected from the group consisting of: hydrogen, C The polyinosine residues include 1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O, or S; each of the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms is independently and as desired substituted with one or more substituents selected from deuterated, halogenated, cyano, nitro, amino, alkyl, carboxyl, alkoxy, or cycloalkyl, wherein the desiredly substituted polyinosine residues contain , where n2 is a number from 4 to 18, and R is selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy.
[0128] For example, where the structural unit -X- is to be replaced as needed. The polyinosine residues that need to be replaced include , where n2 is a number from 4 to 18, and R is selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy.
[0129] For example, where the structural unit -X- is selected from the following group: depending on the need for replacement X1 is selected from the group consisting of: carbonyl, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; X2 is selected from the group consisting of: hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-chain cyclic heteroalkyl containing 1-8 atoms, wherein the heteroalkyl contains 1-3 atoms selected from N, O, or S; and X3 is covalently bonded or selected from the group consisting of: hydrogen, C The polyinosine residues include 1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms, wherein the heteroalkyl comprises 1-3 atoms selected from N, O, or S; each of the C1-C8 alkyl, C1-C8 alkoxy, C1-C6 cycloalkyl, straight-chain heteroalkyl comprising 1-8 atoms, and straight-chain cyclic heteroalkyl comprising 1-8 atoms is independently and as desired substituted with one or more substituents selected from deuterated, halogenated, cyano, nitro, amino, alkyl, carboxyl, alkoxy, or cycloalkyl, wherein the desiredly substituted polyinosine residues contain , where n2 is a number from 4 to 18, and R is selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy.
[0130] For example, n2 can be 4 to 18, 8 to 18, 4 to 12, or 8 to 12. For example, n2 can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
[0131] For example, T may contain compounds with antitumor activity.
[0132] For example, T may contain a topoisomerase inhibitor.
[0133] For example, T can include camptothecin-based and non-camptothecin-based topoisomerase I inhibitors.
[0134] For example, T may include ixanotecan (CAS Registry No. 171335-80-1) and / or belotecone (CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0135] For example, T can be selected from the following group of structures: , and .
[0136] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2): Q1 may include a linker coupled with a thiol group. L1 may contain -L1a-C(=O)-, wherein L1a may be selected from the group consisting of: C1-C7 alkylene groups to be substituted as desired, diethylene glycol to octaethylene glycol groups to be substituted as desired, C3-C6 alicyclic groups to be substituted as desired, aryl groups to be substituted as desired, and heteroaryl groups to be substituted as desired; L2 may contain polypeptide residues composed of amino acids selected from the group consisting of: glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, aspartic acid, and lysine, which may be substituted as needed. L3 can include replacements as needed. , , L2 may contain polyinosinic acid residues. T can contain topoisomerase inhibitors.
[0137] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2): Q1 may include a linker coupled with a thiol group. L1 may contain -L1a-C(=O)-, wherein L1a may be selected from the group consisting of: C1-C7 alkylene groups to be substituted as desired, diethylene glycol to octaethylene glycol groups to be substituted as desired, C3-C6 alicyclic groups to be substituted as desired, aryl groups to be substituted as desired, and heteroaryl groups to be substituted as desired; L2 may contain polypeptide residues composed of amino acids selected from the group consisting of: glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, aspartic acid, and lysine, which may be substituted as needed. L3 can include replacements as needed. , , L3 may contain polyinosinic acid residues. T can contain topoisomerase inhibitors.
[0138] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2): Q1 may include replacements as needed. , L1 may contain -L1a-C(=O)-, wherein L1a may contain C1-C7 alkylene groups that are substituted as desired; L2 may contain structures selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and valine-lysine (Val-Lys). L3 can include replacements as needed. , , L2 may contain lysine residues, and these lysine residues may be substituted as needed. Replace, where n1 is a number from 4 to 18. T may include ixanotecan (Exatecan, CAS Registry No. 171335-80-1) and / or belotecone (Belotecan, CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0139] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C-Trop-2): Q1 can be selected from the following group: depending on the need for replacement. Replace as needed Replace as needed And what needs to be replaced , L1 may contain -L1a-C(=O)-, wherein L1a may contain C1-C7 alkylene groups that are substituted as desired; L2 may contain structures selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), and valine-lysine (Val-Lys). L3 can include replacements as needed. , , L3 can be replaced as needed. Replace, where n² is a number from 4 to 18. T may include ixanotecan (Exatecan, CAS Registry No. 171335-80-1) and / or belotecone (Belotecan, CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0140] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C2-Trop-2):
[0141] Wherein, L may contain a substituted alkylene group, a substituted polyethylene glycol group, or a substituted alicyclic group, depending on the desired substitution; R1 may be an substituted isopropyl group or a substituted benzyl group, depending on the desired substitution; R2 may be a substituted methyl group, a substituted alicyclic group, or a substituted alkylene group, depending on the desired substitution. Or replace as needed R3 can be hydrogen or a methyl group that is substituted as needed; wherein R2 can be substituted as needed. Replacement, where n1 is a number from 4 to 18, and T may contain ixanotecan (Exatecan, CAS Registry No. 171335-80-1) and / or belotecone (Belotecan, CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0142] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C2-Trop-2):
[0143] Wherein, L may contain a substituted alkylene group, a substituted polyethylene glycol group, or a substituted alicyclic group, depending on the desired substitution; R1 may be an substituted isopropyl group or a substituted benzyl group, depending on the desired substitution; R2 may be a substituted methyl group, a substituted alicyclic group, or a substituted alkylene group, depending on the desired substitution. Or replace as needed R3 can be hydrogen or a methyl group that is substituted as needed; wherein R2 can be substituted as needed. Replacement, where n2 is a number from 4 to 18, T may contain ixanotecan (Exatecan, CAS Registry No. 171335-80-1) and / or belotecone (Belotecan, CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0144] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C2-Trop-2):
[0145] Wherein, L may contain a substituted alkylene group, a substituted polyethylene glycol group, or a substituted alicyclic group, depending on the desired substitution; R1 may be an substituted isopropyl group or a substituted benzyl group, depending on the desired substitution; R2 may be a substituted... R3 can be hydrogen or a methyl group that is substituted as needed; wherein, R4 can be substituted as needed. Where n1 is a number from 4 to 18, and T may include ixanotecan (CAS Registry No. 171335-80-1) and / or belotecone (CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0146] For example, this disclosure provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound may comprise the structure shown in formula (C2-Trop-2):
[0147] Wherein, L may contain a substituted alkylene group, a substituted polyethylene glycol group, or a substituted alicyclic group, depending on the desired substitution; R1 may be an substituted isopropyl group or a substituted benzyl group, depending on the desired substitution; R2 may be a substituted methyl group, a substituted alicyclic group, or a substituted alkylene group, depending on the desired substitution. Or replace as needed R3 can be hydrogen or R5; where R5 can be substituted as needed. Where n2 is a number from 4 to 18, and T may include ixanotecan (CAS Registry No. 171335-80-1) and / or belotecone (CAS Registry No. 256411-32-2) and / or Genz-644282 (CAS Registry No. 529488-28-6).
[0148] For example, the Ab may contain an anti-Trop-2 antibody or its antigen-binding fragment.
[0149] For example, the antibody may be selected from the following group: murine antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
[0150] For example, the antibody may contain monoclonal antibodies.
[0151] For example, the antibody may contain a bispecific antibody.
[0152] For example, the antigen-binding fragment may be selected from the following group: Fab, Fab', Fv fragment, F(ab')2, F(ab)2, scFv, di-scFv, VHH and dAb.
[0153] For example, the heavy chains HCDR1, HCDR2 and HCDR3 and the light chains LCDR1, LCDR2 and LCDR3 of the Ab respectively contain the heavy chains HCDR1, HCDR2 and HCDR3 and the light chains LCDR1, LCDR2 and LCDR3 of the anti-Trop-2 antibody.
[0154] For example, the heavy chain variable region VH and light chain variable region VL of the Ab contain the heavy chain variable region VH and light chain variable region VL of the anti-Trop-2 antibody, respectively.
[0155] For example, the heavy and light chains of the Ab may contain the heavy and light chains of the anti-Trop-2 antibody, respectively.
[0156] For example, the Ab may contain sacituzumab (hRS7).
[0157] For example, m can be determined by a method selected from the group consisting of hydrophobic chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, and liquid chromatography-mass spectrometry. For example, m is the average molar ratio of drug molecules to monoclonal antibody molecules in an antibody-drug conjugate obtained by conjugating a single monoclonal antibody molecule with a cytotoxic drug. m can be an integer or decimal from 1 to 8. For example, m can be about 1 to about 2, about 1 to about 3, about 1 to about 4, about 1 to about 5, about 1 to about 6, about 1 to about 7, or about 1 to about 8; for example, m can be about 2 to about 8, about 3 to about 8, about 4 to about 8, about 5 to about 8, about 6 to about 8, about 7 to about 8, or about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8.
[0158] On the other hand, this disclosure also provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
[0159] The compound contains structures selected from the group consisting of: and Ab represents the ligand that can bind to Trop-2, and m is a number from 1 to 8.
[0160] The ligands described in this disclosure can be protein hormones, lectins, growth factors, antibodies, or other molecules capable of binding to cells, receptors, and / or antigens. For example, the ligands disclosed herein can be anti-Trop-2 antibodies or their antigen-binding fragments.
[0161] In this disclosure, the ligand comprises at least one CDR in the variable region (VL) of the antibody light chain. The CDR described in this disclosure may be defined according to Kabat or Chothia; CDR sequences defined in various ways are all included within the scope of protection of this disclosure.
[0162] For example, the antigen-binding protein disclosed herein may be CDR1-3 comprising a heavy chain variable region and a light chain variable region, wherein the CDR1-3 of the heavy chain variable region and the CDR1-3 of the light chain variable region may be the CDR1-3 of the heavy chain variable region and the CDR1-3 of the light chain variable region of sacituzumab, respectively. For example, the antigen-binding protein disclosed herein may have the ability to bind to TROP2.
[0163] For example, the antigen-binding protein disclosed herein may include a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region may be the heavy chain variable region and the light chain variable region of sacituzumab, respectively. For example, the antigen-binding protein disclosed herein may have the ability to bind to TROP2.
[0164] For example, the antigen-binding protein disclosed herein may consist of a heavy chain and a light chain, wherein the heavy chain and the light chain may be the heavy chain and the light chain of Sacituzumab, respectively.
[0165] For example, the heavy chain amino acid sequence of Sacituzumab can be as shown in SEQ ID NO:1, and the light chain amino acid sequence of Sacituzumab can be as shown in SEQ ID NO:2.
[0166] As a significant advantage for verifying the disclosed compounds, the ligands disclosed herein can be, for example, the heavy chain amino acid sequence of sacituzumab can be as shown in SEQ ID NO:1, and the light chain amino acid sequence of sacituzumab can be as shown in SEQ ID NO:2. For example, the heavy chain amino acid sequence of trastuzumab can be as shown in SEQ ID NO:3, and the light chain amino acid sequence of trastuzumab can be as shown in SEQ ID NO:4. For example, the heavy chain amino acid sequence of pertuzumab can be as shown in SEQ ID NO:5, and the light chain amino acid sequence of pertuzumab can be as shown in SEQ ID NO:6. For example, the heavy chain amino acid sequence of enfortumab can be as shown in SEQ ID NO:7, and the light chain amino acid sequence of enfortumab can be as shown in SEQ ID NO:8. For example, the heavy chain amino acid sequence of paltritumab can be as shown in SEQ ID NO:9, and the light chain amino acid sequence of paltritumab can be as shown in SEQ ID NO:10. Similarly, the heavy chain amino acid sequence of antibody H01L02 can be as shown in SEQ ID NO:11, and the light chain amino acid sequence of antibody H01L02 can be as shown in SEQ ID NO:12.
[0167] The antibodies disclosed herein can be prepared using techniques well-known in the field, such as fusion tumor methods, recombinant DNA technology, phage display technology, synthetic techniques, or combinations thereof, or other techniques known in the field. Variants can refer to amino acid sequence mutants of the antibody, as well as covalent derivatives of natural peptides, provided they retain biological activity comparable to the natural peptide. The difference between amino acid sequence mutants and natural amino acid sequences generally lies in the substitution of one or more amino acids in the natural amino acid sequence, or the deletion and / or insertion of one or more amino acids in the peptide sequence. Deletion mutants include fragments of the natural peptide and N-terminal and / or C-terminal truncated mutants. Typically, amino acid sequence mutants exhibit at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% homology to the natural sequence.
[0168] Because the antibody-drug conjugates disclosed herein can target specific cell populations and bind to cell surface-specific proteins (antigens), thereby releasing the drug into the cell in its active form through conjugate endocytosis or drug infiltration, these antibody-drug conjugates can be used to treat target diseases. These antibody-drug conjugates can be administered to subjects (e.g., humans) at therapeutically effective doses via appropriate routes. Subjects requiring treatment may be at risk or suspected of having a condition related to the activity or expression level of a specific antigen. Such patients can be identified through routine physical examinations.
[0169] When treated with the antibody-drug conjugate disclosed herein, delivery can be performed using methods conventional in the art. For example, it can be introduced into cells using liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, or bioadhesive microspheres. Alternatively, the nucleic acid or carrier can be delivered locally by direct injection or by using an infusion pump. Other methods may include using various transport and carrier systems employing conjugates and biodegradable polymers.
[0170] On the one hand, this disclosure provides a pharmaceutical composition that may contain any compound described in this disclosure, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and may contain a pharmaceutically acceptable carrier as needed.
[0171] In addition to the active compound, the pharmaceutical composition described in the application may contain one or more excipients, which may be selected from the group consisting of fillers (diluents), binders, wetting agents, disintegrants, and excipients. Depending on the method of administration, the composition may contain 0.1% to 99% by weight of the active compound.
[0172] Pharmaceutical compositions containing active ingredients may be in oral forms, such as tablets, sugar lozenges, tablets, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and may contain binders, fillers, lubricants, disintegrants, or pharmaceutically acceptable wetting agents, and may also contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives.
[0173] Aqueous suspensions may contain active substances and excipients suitable for mixing. Aqueous suspensions may also contain one or more preservatives, such as one or more colorants, one or more flavoring agents, and one or more sweeteners. Oil suspensions can be prepared by suspending the active ingredient in vegetable oil. Oil suspensions may contain thickeners. The aforementioned sweeteners and flavoring agents may also be added.
[0174] Pharmaceutical formulations can also be dispersible powders and granules used to prepare aqueous suspensions, providing the active ingredient by adding one or more of a water-based dispersant, wetting agent, suspending agent, or preservative. Other excipients, such as sweeteners, flavoring agents, and coloring agents, may also be added. These formulations are preserved by adding antioxidants such as ascorbic acid. The pharmaceutical formulations disclosed herein can also be in the form of oil-in-water emulsions.
[0175] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient may be dissolved in a mixture of soybean oil and lecithin. The oil solution may then be treated with a mixture of water and glycerol to form a microemulsion. The injection solution or microemulsion may be injected into the patient's bloodstream via local large-volume injection. Alternatively, the solution and microemulsion may be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous delivery device may be used. For example, this device may be an intravenous infusion pump.
[0176] Pharmaceutical formulations may be in the form of sterile injectable water or oil suspensions for intramuscular and subcutaneous administration. These suspensions may be formulated using known techniques with suitable dispersants or wetting agents and suspending agents as described above. Sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral acceptable, non-toxic diluents or solvents. Alternatively, sterile fixative oils may be conveniently used as solvents or suspension media.
[0177] The disclosed compounds can be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug. Such substances include cocoa butter, glycerin gelatin, hydrogenated vegetable oils, polyethylene glycol of various molecular weights, and mixtures of polyethylene glycol fatty acid esters.
[0178] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, weight, health status, behavior, diet, timing of administration, route of administration, rate of excretion, and combination of drugs; furthermore, the optimal treatment modality, such as the treatment pattern, the daily dosage or type of pharmaceutically acceptable salt of the compound disclosed herein or its tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, and / or the tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, and / or pharmaceutically acceptable salts thereof, can be verified based on conventional treatment regimens.
[0179] The pharmaceutical composition disclosed herein may contain a safe and effective amount of the disclosed antibody-drug conjugate and a pharmaceutically acceptable carrier. Such carriers may include (but are not limited to): saline, buffer solutions, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the pharmaceutical formulation should be matched to the route of administration. The pharmaceutical composition disclosed herein may be prepared in solution form, for example, using physiological saline or an aqueous solution containing glucose and other excipients by conventional methods. The pharmaceutical composition may be manufactured under aseptic conditions. The dosage of the active ingredient may be a therapeutically effective amount.
[0180] The effective amount of the antibody-drug conjugate disclosed herein can vary depending on the administration method and the severity of the disease to be treated. The selection of the effective amount can be determined by someone skilled in the art based on various factors (e.g., through clinical trials). These factors may include, but are not limited to: the pharmacokinetic parameters of the bifunctional antibody-drug conjugate, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. Generally, satisfactory results can be obtained when the antibody-drug conjugate disclosed herein is administered daily at an appropriate dose. For example, due to the urgency of the treatment condition, several separate doses may be administered daily, or the dose may be reduced proportionally.
[0181] The disclosed compound can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents. When using pharmaceutical compositions, a safe and effective amount of the disclosed compound can be applied to mammals (such as humans) requiring treatment, wherein the dose administered can be a pharmaceutically considered effective dose, and the specific dose can also take into account factors such as the route of administration and the patient's health condition.
[0182] This disclosure provides the use of the disclosed compound, or its tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, or its pharmaceutically acceptable salts, prodrugs, or solvates, and / or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment and / or prevention of tumors. For example, the tumor may be selected from tumors associated with the expression of a target group such as HER2. For example, the tumor associated with the expression of this target includes tumors with high expression of this target and / or tumors positive for this target. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor is selected from the following groups: breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma, and mesothelioma.
[0183] This disclosure provides the use of a compound of this disclosure, or a tautomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and / or a pharmaceutical composition thereof, in a medicament for the treatment and / or prevention of tumors. For example, the tumor may be selected from tumors associated with the expression of a target group such as HER2. For example, the tumor associated with the expression of this target includes tumors with high expression of this target and / or tumors positive for this target. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor is selected from the following groups: breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma, and mesothelioma.
[0184] This disclosure provides a method for preventing and / or treating tumors, which may include administering to a subject a compound disclosed herein, or a tautomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and / or a pharmaceutical composition disclosed herein. For example, the tumor may be selected from tumors associated with the expression of a target group such as HER2. For example, the tumor associated with the expression of this target includes tumors with high expression of this target and / or tumors positive for this target. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor is selected from the following groups: breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma, and mesothelioma.
[0185] The examples described below are not intended to be limited by any theory, but are merely for illustrating the compounds, preparation methods and uses disclosed herein, and are not intended to limit the scope of the invention disclosed herein. [Example]
[0186] [Example 1: Synthesis and Preparation of Compounds] The raw materials disclosed herein are commercially available products, or can be prepared by methods known in the art or according to the methods described herein. Specifically, Fmoc is a 9-fluorenylmethyloxycarbonyl protecting group, Boc is a tert-butoxycarbonyl protecting group, and TBDMS / TBS is a tert-butyldimethylsilyl protecting group.
[0187] [Synthesis of compound (A-1)]
[0188] Synthesis route:
[0189] [Step 1: Synthesis of Intermediate 1-1] Fmoc-Val-OSu (100 g, 229 mmol) was dissolved in 500 mL of tetrahydrofuran, and Nε-(tert-butoxycarbonyl)-L-lysine (59.3 g, 241 mmol) and sodium bicarbonate (20.21 g, 241 mmol) in 500 mL of aqueous solution were added separately. The reaction solution was stirred at room temperature for 48 hours, and the reaction was checked for completeness. The pH of the reaction solution was adjusted to about 6 with 1N dilute hydrochloric acid, and 500 mL of ethyl acetate was added for extraction. After separating the organic phase, the product was washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness. The residue was recrystallized from methyl tert-butyl ether to give product 1-1 (107 g, yield 82%) as a white solid. LC-MS (ESI, m / z) theoretical value: 567.29, measured value: 568.26 (M+H).
[0190] [Step 2: Synthesis of Intermediates 1-2] Intermediate 1-1 (60 g, 106 mmol) was dissolved in a mixed solvent of dichloromethane and methanol (v:v = 2:1, 900 mL). p-Aminobenzyl alcohol (19.52 g, 159 mmol) was added at room temperature, followed by EEDQ (39.2 g, 159 mmol). The reaction mixture was stirred at room temperature for 24 hours, then evaporated to dryness under reduced pressure. Ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with ether, and dried to obtain intermediate 1-2 (51 g, 72% yield). LC-MS (ESI, m / z) theoretical value: 672.35, measured value: 673.37 (M+H).
[0191] [Step 3: Synthesis of Intermediates 1-3] Intermediate 1-2 (50 g, 74.3 mmol) was dissolved in 370 mL of DMF. Diethylamine (78 mL, 743 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 2 hours, then evaporated to dryness under reduced pressure. Acetic acid and acetic acid were added, and the mixture was stirred until a solid precipitated. The solid was filtered, washed several times with ether, and dried to obtain intermediate 1-3 (31.5 g, 94% yield). LC-MS (ESI, m / z) theoretical value: 450.28, measured value: 451.32 (M+H).
[0192] [Step 4: Synthesis of intermediates 1-4] Intermediate 1-3 (5 g, 11.10 mmol) was dissolved in 100 mL of DMF. Maleiminoacetic acid succinimide (2.80 g, 11.10 mmol) was added at room temperature. The reaction mixture was stirred overnight at room temperature. The reaction mixture was evaporated to dryness under reduced pressure. Methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 1-4, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 587.30, measured value: 588.31 (M+H).
[0193] [Step 5: Synthesis of intermediates 1-5] Intermediates 1-4 (2 g, 3.40 mmol) were dissolved in 40 mL of DMF. DIPEA (1.189 mL, 6.81 mmol) and bis(4-nitrophenyl) carbonate (1.553 g, 5.10 mmol) were added separately at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. Methyl tributyl ether was added and stirred until a solid precipitated. The mixture was filtered, and the solid was washed several times with diethyl ether. After drying, intermediates 1-5 were obtained and used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 752.30, measured value: 753.31 (M+H).
[0194] [Step 6: Synthesis of intermediates 1-6] Intermediate 1-5 (142 mg, 0.188 mmol) was dissolved in 400 μL of anhydrous DMF, followed by 100 μL of anhydrous pyridine, then ethatecan mesylate (purchased from Shanghai Haoyuan, 100 mg, 0.188 mmol) and HOBt (25.4 mg, 0.188 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. The reaction solution was purified by reversed-phase HPLC to obtain intermediate 1-6 (80 mg, 40% yield). LC-MS (ESI, m / z) theoretical value: 1048.43, measured value: 1045.45 (M+H).
[0195] [Step 7: Synthesis of compound (A-1)] Intermediate 1-6 (100 mg, 0.095 mmol) was dissolved in 1 mL of anhydrous dichloromethane. 500 μL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the final product, which was then purified by reversed-phase HPLC to obtain the final product compound (A-1) (70 mg, yield 77%). LC-MS (ESI, m / z) theoretical value: 1048.43, measured value: 1045.45 (M+H). LC-MS (ESI, m / z) theoretical value: 948.38, measured value: 949.37 (M+H).
[0196] [Synthesis of compound (A-2)] The synthesis of compound (A-2) followed the same steps as that of compound (A-1), except that the starting material maleiminoacetic acid succinimide in step 4 was replaced with 6-(maleimino)hexanoic acid succinimide ester. After several reaction steps, product (A-2) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1004.44, measured value: 1005.45 (M+H).
[0197] [Synthesis of compound (A-3)] Compound (A-1) (100 mg, 0.105 mmol) was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH, 97 mg, 0.126 mmol), HATU (48 mg, 0.126 mmol), and DIPEA (37 μL, 0.211 mmol) were added separately. The mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure to obtain the final product. The final product compound (A-3) (87 mg, yield 49%) was then purified by reversed-phase HPLC. The theoretical value of LC-MS (ESI, m / z) was 1700.76, and the measured value was 1701.78 (M+H).
[0198] [Synthesis of compound (A-4)] Compound (A-2) (100 mg, 0.099 mmol) was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH, 92 mg, 119 mmol), HATU (45 mg, 119 mmol), and DIPEA (35 μL, 0.199 mmol) were added separately. The mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure to obtain the final product. The final product compound (A-4) (95 mg, yield 54%) was then purified by reversed-phase HPLC. The theoretical value of LC-MS (ESI, m / z) was 1756.83, and the measured value was 1757.85 (M+H).
[0199] [Synthesis of compound (A-5)] The synthesis of compound (A-5) followed the same steps as that of compound (A-4), except that acetylated-10 polyinosine (Ac-Sar10-COOH) was replaced with acetylated-4 polyinosine (Ac-Sar4-COOH) in the last step. After several reaction steps, product (A-5) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1330.60, measured value: 1331.61 (M+H).
[0200] [Synthesis of compound (A-6)] The synthesis of compound (A-6) followed the same steps as that of compound (A-4), except that ethatecan mesylate in step 6 was replaced with beloteccan hydrochloride (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-6) was obtained as a white amorphous powder. LC-MS (ESI, m / z) theoretical value: 1754.87, measured value: 1755.88 (M+H).
[0201] [Synthesis of compound (A-7)] The synthesis of compound (A-7) followed the same steps as that of compound (A-4), except that Fmoc-Val-OSu in step 1 was replaced with Fmoc-Phe-OSu. After several reaction steps, product (A-7) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1804.83, measured value: 1805.85 (M+H).
[0202] [Synthesis of compound (A-8)] The synthesis of compound (A-8) followed the same steps as that of compound (A-7), except that ethatecan mesylate in step 6 was replaced with beloteccan hydrochloride (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-8) was obtained as a white amorphous powder. LC-MS (ESI, m / z) theoretical value: 1802.87, measured value: 1803.86 (M+H).
[0203] [Synthesis of compound (A-9)]
[0204] Synthesis route:
[0205] [Step 1: Synthesis of Intermediate 9-1] Intermediates 9-1A (1.3 g, 2.69 mmol) and 9-1B (1.35 g, 2.69 mmol) were dissolved in a mixed solvent of dichloromethane and methanol (v:v = 2:1, 90 mL). EEDQ (800 mg, 3.23 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 24 hours, evaporated to dryness under reduced pressure, and 9-1 (1.8 g, 69% yield) was obtained by column chromatography. LC-MS (ESI, m / z) theoretical value: 966.49, measured value: 967.50 (M+H).
[0206] [Step 2: Synthesis of Intermediate 9-2] Intermediate 9-1 (900 mg, 0.93 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran and cooled in an ice bath under an argon atmosphere. A hydrofluoric acid pyridine complex (1.8 g, 18.61 mmol) was added, and the reaction mixture was stirred at 0°C for 2 hours. The reaction was quenched with water, extracted with dichloromethane, and the organic layer was separated. After drying with anhydrous sodium sulfate, column chromatography was used to obtain intermediate 9-2 (610 mg, 77% yield). LC-MS (ESI, m / z) theoretical value: 852.41, measured value: 853.43 (M+H).
[0207] [Step 3: Synthesis of Intermediate 9-3] Intermediate 9-2 (600 mg, 0.703 mmol) was dissolved in 4 mL of anhydrous DMF. DIPEA (0.84 mL, 1.05 mmol) and bis(4-nitrophenyl) carbonate (321 mg, 1.05 mmol) were added separately at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. The solvent was removed by vacuum distillation, and then methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 9-3, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 1017.41, measured value: 1018.38 (M+H).
[0208] [Step 4: Synthesis of Intermediate 9-4] Intermediate 9-3 (300 mg, 0.295 mmol) was dissolved in 400 μL of anhydrous DMF, followed by 100 μL of anhydrous pyridine, then ethatecan mesylate (purchased from Shanghai Haoyuan, 157 mg, 0.295 mmol) and HOBt (40 mg, 0.295 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. The reaction solution was purified by reversed-phase HPLC to obtain intermediate 9-4 (160 mg, yield 41%). LC-MS (ESI, m / z) theoretical value: 1313.54, measured value: 1314.51 (M+H).
[0209] [Step 5: Synthesis of Intermediate 9-5] Intermediate 9-4 (150 mg, 0.114 mmol) was dissolved in 1 mL of DMF. Diethylamine (120 μL, 1.14 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 2 hours, and then evaporated under reduced pressure to obtain intermediate 9-5, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 1091.48, measured value: 1092.51 (M+H).
[0210] [Step 6: Synthesis of Intermediate 9-6] Compound 9-5 (120 mg, 0.110 mmol) was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH, 102 mg, 0.132 mmol), HATU (50 mg, 0.132 mmol), and DIPEA (38 μL, 0.22 mmol) were added separately. The mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure to obtain the final product, which was then purified by reversed-phase HPLC to obtain intermediate compound 9-6 (105 mg, yield 52%). LC-MS (ESI, m / z) theoretical value: 1843.86, measured value: 1844.84 (M+H).
[0211] [Step 7: Synthesis of compound (A-9)] Intermediate 9-6 (100 mg, 0.054 mmol) was dissolved in 1 mL of anhydrous dichloromethane. 500 μL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the final product, which was then purified by reversed-phase HPLC to obtain the final product compound (A-9) (57 mg, 60% yield). LC-MS (ESI, m / z) theoretical value: 1048.43, measured value: 1045.45 (M+H). LC-MS (ESI, m / z) theoretical value: 1743.81, measured value: 1744.85 (M+H).
[0212] [Synthesis of compound (A-10)]
[0213] The synthesis of compound (A-10) followed the same steps as that of compound (A-9), except that ethatecan mesylate in step 4 was replaced with beloteccan hydrochloride (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-10) was obtained as a white amorphous powder. LC-MS (ESI, m / z) theoretical value: 1741.85, measured value: 1742.83 (M+H).
[0214] [Synthesis of compound (A-11)]
[0215] Synthesis route: [Step 1: Synthesis of Intermediate 11-1] Intermediate 11-1A (Mc-Val-Ala-OH, purchased from Shanghai Haoyuan Chemical, 2.4 g, 6.29 mmol) and 11-1B (3.18 g, 6.29 mmol) were dissolved in a mixed solvent of dichloromethane and methanol (v:v = 2:1, 90 mL). EEDQ (1.86 g, 7.55 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 24 hours, evaporated to dryness under reduced pressure, and 11-1 (3.9 g, 71% yield) was obtained by column chromatography. LC-MS (ESI, m / z) theoretical value: 867.46, measured value: 868.49 (M+H).
[0216] [Step 2: Synthesis of Intermediate 11-2] Intermediate 11-1 (2 g, 2.3 mmol) was dissolved in 50 mL of anhydrous tetrahydrofuran and cooled in an ice bath under an argon atmosphere. A hydrofluoric acid pyridine complex (4.6 g, 46 mmol) was added, and the reaction mixture was stirred at 0°C for 2 hours. The reaction was quenched with water, extracted with dichloromethane, and the organic layer was separated. After drying with anhydrous sodium sulfate, intermediate 11-2 (1.1 g, 76% yield) was obtained by column chromatography. Theoretical LC-MS (ESI, m / z): 629.34; Measured: 630.31 (M+H).
[0217] [Step 3: Synthesis of Intermediate 11-3] Intermediate 11-2 (700 mg, 1.11 mmol) was dissolved in 4 mL of anhydrous DMF. DIPEA (0.39 mL, 2.23 mmol) and bis(4-nitrophenyl) carbonate (406 mg, 1.33 mmol) were added separately at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. The solvent was removed by vacuum distillation, and then methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 11-3, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 794.35, measured value: 795.41 (M+H).
[0218] [Step 4: Synthesis of intermediate 11-4] Intermediate 11-3 (300 mg, 0.44 mmol) was dissolved in 400 μL of anhydrous DMF, followed by 100 μL of anhydrous pyridine, then ethatecan mesylate (purchased from Shanghai Haoyuan, 234 mg, 0.44 mmol) and HOBt (60 mg, 0.44 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. The reaction solution was purified by reversed-phase HPLC to obtain intermediate 11-4 (230 mg, yield 48%). LC-MS (ESI, m / z) theoretical value: 1090.48, measured value: 1091.53 (M+H).
[0219] [Step 5: Synthesis of intermediate 11-5] Intermediate 11-4 (200 mg, 0.183 mmol) was dissolved in 1 mL of anhydrous dichloromethane. 300 μL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the trifluoroacetate salt of intermediate 11-5, which was used directly in the next reaction without further purification. LC-MS (ESI, m / z) theoretical value: 990.43, measured value: 991.47 (M+H).
[0220] [Step 6: Synthesis of compound (A-11)] Compound 11-5 (120 mg, 0.109 mmol) was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH, 84 mg, 0.109 mmol), HATU (50 mg, 0.130 mmol), and DIPEA (38 μL, 0.22 mmol) were added separately. The mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure to obtain the final product, which was then purified by reversed-phase HPLC to obtain compound (A-11) (74 mg, yield 38%). LC-MS (ESI, m / z) theoretical value: 1742.81, measured value: 1743.85 (M+H).
[0221] [Synthesis of compound (A-12)]
[0222] The synthesis of compound (A-12) followed the same steps as that of compound (A-11), except that the starting material Ac-Sar10-COOH in step 6 was replaced with Ac-Sar4-COOH. After several reaction steps, product (A-12) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1316.59, measured value: 1317.62 (M+H).
[0223] [Synthesis of compound (A-13)]
[0224] The synthesis of compound (A-13) followed the same steps as that of compound (A-11), except that the starting material 11-1A in step 1 was replaced with Mc-Val-Cit-OH (purchased from Shanghai Haoyuan Chemical). After several reaction steps, the product (A-13) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1828.86, measured value: 1829.88 (M+H).
[0225] [Synthesis of compound (A-14)]
[0226] The synthesis of compound (A-14) followed the same steps as that of compound (A-11), except that the starting material 11-1A (Mc-VA-OH) in step 1 was replaced with Mc-GGFG-OH (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-13) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1890.84, measured value: 1891.90 (M+H).
[0227] [Synthesis of compound (A-15)]
[0228] Synthesis route:
[0229] [Step 1: Synthesis of Intermediate 15-2] Intermediates 15-1A (2.3 g, 8.57 mmol) and 15-1B (3.74 g, 8.57 mmol) were dissolved in a mixture of dichloromethane and methanol (v:v = 2:1, 90 mL). P-EEDQ (4.24 g, 17.15 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 24 hours, then evaporated to dryness under reduced pressure. Intermediate 15-2 (3.23 g, 4.70 mmol, 54.9% yield) was obtained by column chromatography. LC-MS (ESI, m / z) theoretical value: 686.27, measured value: 687.21 (M+H).
[0230] [Step 2: Synthesis of Intermediate 15-3] Intermediate 15-2 (2.3 g, 3.35 mmol) was dissolved in 40 mL of anhydrous DMF. DIPEA (1.170 mL, 6.70 mmol) and bis(4-nitrophenyl) carbonate (1.528 g, 5.02 mmol) were added separately at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. The solvent was removed by vacuum distillation, and then methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 15-3 (2.1 g, 2.465 mmol, yield 73.6%), which was used directly in the next reaction.
[0231] [Step 3: Synthesis of Intermediate 15-4] Intermediate 15-3 (400 mg, 0.470 mmol) was dissolved in 4 mL of anhydrous DMF, followed by 1 mL of anhydrous pyridine, then ethatecan free base (purchased from Shanghai Haoyuan Chemical) (204 mg, 0.470 mmol) and HOBt (63.4 mg, 0.470 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. After evaporation to dryness, the solution was purified by column chromatography (DCM:MeOH = 30:1) to give intermediate 15-4 (244 mg, 0.213 mmol, yield 45.3%). LC-MS (ESI, m / z) theoretical value: 1147.41, measured value: 1148.48 (M+H).
[0232] [Step 4: Synthesis of Intermediate 15-5] Intermediate 15-4 (200 mg, 0.183 mmol) was dissolved in 1 mL of anhydrous dichloromethane. 300 μL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the trifluoroacetate salt of intermediate 15-5, which was used directly in the next reaction without further purification. LC-MS (ESI, m / z) theoretical value: 1047.36, measured value: 1048.40 (M+H).
[0233] [Step 5: Synthesis of Compound A-15] Intermediate compound 15-5 (150 mg, 0.131 mmol) was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH) (101 mg, 0.131 mmol), DIPEA (114 μl, 0.654 mmol), and HATU (74.6 mg, 0.196 mmol) were added separately. The mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure to obtain the final product. The final product was then purified by reversed-phase HPLC to obtain compound A-15 (107 mg, 0.059 mmol, yield 45.4%). LC-MS (ESI, m / z) theoretical value: 1799.74, measured value: 1800.77 (M+H).
[0234] [Synthesis of compound (A-16)]
[0235] The synthesis of compound (A-16) followed the same steps as that of compound (A-15), except that ethatecan mesylate in step 3 was replaced with beloteccan hydrochloride (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-16) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1797.78, measured value: 1798.81 (M+H).
[0236] [Synthesis of compound (A-17)]
[0237] The synthesis of compound (A-17) followed the same steps as that of compound (A-11), except that ethatecan mesylate in step 4 was replaced with Genz-644282 (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-17) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1714.80, measured value: 1715.83 (M+H).
[0238] [Synthesis of compound (A-18)]
[0239] Synthesis route:
[0240] [Step 1: Synthesis of Intermediate 18-2] Intermediate 18-1A (purchased from Shanghai Bid Pharmaceutical, 4.94 g, 14.82 mmol) and 15-1B (synthesized according to the method in WO2016038383, 6.04 g, 14.82 mmol) were dissolved in a mixed solvent of dichloromethane and methanol (v:v = 2:1, 120 mL). EEDQ (7.33 g, 29.6 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 24 hours, then evaporated to dryness under reduced pressure. The product was filtered through ether with stirring, and then dried under vacuum to obtain intermediate 18-2 (6.3 g, 59% yield). LC-MS (ESI, m / z) theoretical value: 726.40, measured value: 727.41 (M+H).
[0241] [Step 2: Synthesis of Intermediate 18-3] Intermediate 18-2 (3.0 g, 4.13 mmol) was dissolved in 50 mL of THF, and 10% Pd-C (800 mg) was added. After hydrogenation at atmospheric pressure for 8 hours, the reaction was confirmed to be complete by TLC. Palladium on carbon was removed by filtration, and the reaction solution was evaporated to dryness and used directly for the next step of the reaction. Theoretical LC-MS (ESI, m / z) value: 636.36, measured value: 637.34 (M+H).
[0242] [Step 3: Synthesis of intermediate 18-4] Intermediate compound 18-3 (2.6 g, 4.08 mmol) was dissolved in 100 mL of anhydrous DMF. N-(2-aminoethyl)maleimine hydrochloride (721 mg, 4.08 mmol), DIPEA (1.42 mL, 8.17 mmol), and HATU (2.0 g, 5.31 mmol) were added separately. The mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure to obtain the final product, which was then purified by column chromatography to give compound 18-4 (2.2 g, 71% yield). LC-MS (ESI, m / z) theoretical value: 758.40, measured value: 759.42 (M+H).
[0243] [Step 4: Synthesis of Intermediate 18-5] Intermediate 18-4 (1.0 g, 1.32 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran and cooled in an ice bath under an argon atmosphere. A hydrofluoric acid pyridine complex (2.6 g, 26.4 mmol) was added, and the reaction mixture was stirred at 0°C for 2 hours. The reaction was quenched with water, extracted with dichloromethane, and the organic layer was separated. After drying with anhydrous sodium sulfate, intermediate 18-5 (570 mg, yield 67%) was obtained by column chromatography. Theoretical LC-MS (ESI, m / z): 644.32; Measured value: 645.35 (M+H).
[0244] [Step 5: Synthesis of intermediate 18-6] Intermediate 18-5 (500 mg, 0.776 mmol) was dissolved in 10 mL of anhydrous DMF. DIPEA (271 μl, 1.55 mmol) and bis(4-nitrophenyl) carbonate (236 mg, 0.776 mmol) were added separately at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. The solvent was removed by vacuum distillation, and then methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 18-6 (530 mg, 84% yield), which was used directly in the next reaction.
[0245] [Step 6: Synthesis of intermediate 18-7] Intermediate 18-6 (400 mg, 0.494 mmol) was dissolved in 4 mL of anhydrous DMF, followed by 1 mL of anhydrous pyridine, then ethatecan mesylate (purchased from Shanghai Haoyuan, 263 mg, 0.494 mmol) and HOBt (66.7 mg, 0.494 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. The reaction solution was purified by reversed-phase HPLC to obtain intermediate 18-7 (320 mg, yield 58%). LC-MS (ESI, m / z) theoretical value: 1105.46, measured value: 1106.48 (M+H).
[0246] [Step 7: Synthesis of intermediate 18-8] Intermediate 15-4 (300 mg, 0.27 mmol) was dissolved in 3 mL of anhydrous dichloromethane. 1 mL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the trifluoroacetate salt of intermediate 18-8, which was used directly in the next reaction without further purification. LC-MS (ESI, m / z) theoretical value: 1005.40, measured value: 1006.41 (M+H).
[0247] [Step 8: Synthesis of Compound A-18] Intermediate compound 15-5 (300 mg, 0.268 mmol) was dissolved in 5 mL of anhydrous DMF. Acetyl-10 polyinosinic acid (Ac-Sar10-COOH) (206 mg, 0.268 mmol), DIPEA (94 μl, 0.536 mmol), and HATU (122 mg, 0.321 mmol) were added separately. The mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure to obtain the final product. The final product was then purified by reversed-phase HPLC to obtain compound A-18 (170 mg, 36% yield). LC-MS (ESI, m / z) theoretical value: 1757.78, measured value: 1758.82 (M+H).
[0248] [Synthesis of compound (A-19)]
[0249] The synthesis of compound (A-19) followed the same steps as that of compound (A-18), except that N-(2-aminoethyl)maleimine hydrochloride in step 3 was replaced with 2-(methylsulfonylmethane)benzo[d]thiazol-6-amine. After several reaction steps, product (A-19) was obtained. LC-MS (ESI, m / z) theoretical value: 1845.73, measured value: 1846.75 (M+H).
[0250] [Synthesis of compound (A-20)]
[0251] The synthesis of compound (A-20) followed the same steps as that of compound (A-18), except that N-(2-aminoethyl)maleimide hydrochloride in step 3 was replaced with 4-(5-(methylsulfonylurea)-1,3,4-oxadiazol-2-yl)aniline. After several reaction steps, product (A-20) was obtained. Theoretical LC-MS (ESI, m / z) value: 1856.76, measured value: 1857.80 (M+H).
[0252] [Synthesis of compound (A-21)]
[0253] The synthesis of compound (A-21) follows the same steps as that of compound (A-11), except that the intermediate in step 1 is used instead of the intermediate in step 2. Replace with After several reaction steps, product (A-21) was obtained. Theoretical LC-MS (ESI, m / z) value: 1742.81, measured value: 1743.85 (M+H).
[0254] [Synthesis of compound (A-22)]
[0255] The synthesis of compound (A-22) followed the same steps as that of compound (A-21), except that the starting material Mc-Val-Ala-OH in step 1 was replaced with Mc-Val-Cit-OH. After several reaction steps, product (A-22) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1828.86, measured value: 1829.87 (M+H).
[0256] [Synthesis of compound (A-23)]
[0257] The synthesis of compound (A-23) followed the same steps as that of compound (A-21), except that the starting material Mc-Val-Ala-OH in step 1 was replaced with Mc-GGFG-OH. After several reaction steps, product (A-23) was obtained as a beige amorphous powder. LC-MS (ESI, m / z) theoretical value: 1890.84, measured value: 1891.86 (M+H).
[0258] [Synthesis of compound (A-28)]
[0259] Synthesis route:
[0260] [Step 1: Synthesis of Intermediate 28-1] 10 g (55.8 mmol) of 6-nitrosobenzofuran-1(3H)-one and 9.84 g (61.4 mmol) of tributyl (2-aminoethyl)carbamate were weighed into a 100 mL round-bottom flask and heated to 90 °C with stirring overnight. Methyl tributyl ether (MTBE) was added and stirred. The mixture was filtered, and the solid was washed several times with MTBE and dried under vacuum to obtain intermediate 28-1 (13.6 g, yield 72%). LC-MS (ESI, m / z) theoretical value: 339.14, measured value: 340.17 (M+H).
[0261] [Step 2: Synthesis of Intermediate 28-2] Intermediate 28-1 (10 g, 29.5 mmol) and imidazole (8.02 g, 118 mmol) were dissolved in 300 mL of dichloromethane. TBS-Cl (6.66 g, 44.2 mmol) was added under ice-bath cooling, and the mixture was stirred overnight at room temperature. The reaction solution was quenched with water to extinguish the reaction. After separating the organic phase, the mixture was washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness. The crude product was purified by column chromatography to give intermediate 28-2 (12.3 g, 92% yield). LC-MS (ESI, m / z) theoretical value: 453.23, measured value: 454.33 (M+H).
[0262] [Step 3: Synthesis of Intermediate 28-3] Intermediate 28-2 (6.0 g, 13.23 mmol) was dissolved in THF:EtOH (1:1) (500 mL). 1 g of 10% Pd-C was added under argon atmosphere, followed by ammonium formate (8.34 g, 132 mmol). The mixture was stirred overnight at room temperature, filtered to remove palladium on carbon, and the filtrate was evaporated to dryness. Dichloromethane and water were added to separate the organic phase. The mixture was then washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness to obtain intermediate 28-3 (5.6 g, 100%). LC-MS (ESI, m / z) theoretical value: 423.26, measured value: 424.31 (M+H).
[0263] [Step 4: Synthesis of intermediate 28-4] Intermediate 28-3 (5.5 g, 12.98 mmol) and Fmoc-Val-Alal-OH (5.33 g, 12.98 mmol) were dissolved in a mixed solvent of dichloromethane and methanol (v:v = 2:1, 300 mL). EEDQ (4.82 g, 19.47 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 24 hours, then evaporated to dryness under reduced pressure. Ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with ether, and dried to obtain intermediate 28-4 (6.4 g, 60% yield). LC-MS (ESI, m / z) theoretical value: 815.43, measured value: 816.48 (M+H).
[0264] [Step 5: Synthesis of intermediate 28-5] Intermediate 28-4 (6.0 g, 7.35 mmol) was dissolved in 100 mL of DMF. Diethylamine (7.68 mL, 73.5 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 2 hours, then evaporated to dryness under reduced pressure. Acetic acid and ether were added and stirred until a solid precipitated. The mixture was filtered, and the solid was washed several times with ether. After drying, intermediate 28-5 (4.3 g, 98% yield) was obtained. LC-MS (ESI, m / z) theoretical value: 593.36, measured value: 594.40 (M+H).
[0265] [Step 6: Synthesis of intermediate 28-6] Intermediate 28-5 (4.0 g, 6.74 mmol) was dissolved in 100 mL of DMF. Maleiminoacetic acid succinimide (2.07 g, 6.74 mmol) was added at room temperature. The reaction mixture was stirred overnight at room temperature. The reaction mixture was evaporated to dryness under reduced pressure. Methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 28-6, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 786.43, measured value: 787.45 (M+H).
[0266] [Step 7: Synthesis of intermediate 28-7] Intermediate 28-6 (3.5 g, 4.45 mmol) was dissolved in 100 mL of anhydrous tetrahydrofuran and cooled in an ice bath under an argon atmosphere. A hydrofluoric acid pyridine complex (8.8 g, 89 mmol) was added, and the reaction mixture was stirred at 0°C for 2 hours. The reaction was quenched with water, extracted with dichloromethane, and the organic layer was separated. After drying with anhydrous sodium sulfate, intermediate 28-7 (1.6 g, 53% yield) was obtained by column chromatography. Theoretical LC-MS (ESI, m / z): 672.35; Measured value: 673.37 (M+H).
[0267] [Step 8: Synthesis of intermediate 28-8] Intermediate 28-7 (1.0 g, 1.49 mmol) was dissolved in 20 mL of anhydrous DMF. DIPEA (0.519 mL, 2.97 mmol) and bis(4-nitrophenyl) carbonate (678 mg, 2.23 mmol) were added at room temperature. The mixture was stirred overnight at room temperature under argon atmosphere. The solvent was removed by vacuum distillation, and then methyl tributyl ether was added and stirred until a solid precipitated. The solid was filtered, washed several times with diethyl ether, and dried to obtain intermediate 28-8, which was used directly in the next reaction. LC-MS (ESI, m / z) theoretical value: 837.35, measured value: 838.36 (M+H).
[0268] [Step 9: Synthesis of intermediates 28-9] Intermediate 28-8 (300 mg, 0.358 mmol) was dissolved in 4 mL of anhydrous DMF, followed by 1 mL of anhydrous pyridine, then ethatecan mesylate (purchased from Shanghai Haoyuan, 190 mg, 0.358 mmol) and HOBt (55 mg, 0.358 mmol). The mixture was stirred overnight at room temperature under argon atmosphere. The reaction solution was purified by reversed-phase HPLC to obtain intermediate 28-9 (234 mg, yield 58%). LC-MS (ESI, m / z) theoretical value: 1133.49, measured value: 1134.52 (M+H).
[0269] [Step 10: Synthesis of intermediate 28-10] Intermediate 28-10 (200 mg, 0.176 mmol) was dissolved in 1 mL of anhydrous dichloromethane. 300 μL of trifluoroacetic acid was added under ice bath conditions, and the mixture was stirred for 30 minutes after returning to room temperature. The solvent was removed under reduced pressure to obtain the trifluoroacetate salt of intermediate 28-10, which was used directly in the next reaction without further purification. LC-MS (ESI, m / z) theoretical value: 1033.43, measured value: 1034.45 (M+H).
[0270] [Step 11: Synthesis of compound A28] Compound 28-10 obtained in step 10 was dissolved in 1 mL of anhydrous DMF. Acetyl-10 polyinosine (Ac-Sar10-COOH, 136 mg, 0.176 mmol), HATU (87 mg, 0.229 mmol), and DIPEA (154 μL, 0.88 mmol) were added separately. The mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure to obtain the final product. The final product was then purified by reversed-phase HPLC to obtain compound (A-11) (135 mg, yield 43%). Theoretical LC-MS (ESI, m / z): 1785.82, measured value: 1786.85 (M+H).
[0271] [Synthesis of compound (A-29)]
[0272] The synthesis of compound (A-29) followed the same steps as that of compound (A-11), except that ethatecan mesylate in step 4 was replaced with beloteccan hydrochloride (purchased from Shanghai Haoyuan Chemical). After several reaction steps, product (A-29) was obtained as a white amorphous powder. LC-MS (ESI, m / z) theoretical value: 1740.85, measured value: 1741.82 (M+H).
[0273] Synthesis of AP-1, the PEG derivative corresponding to A-11 molecule
[0274] The synthesis of compound (AP-1) followed the same steps as that of compound (A-11), except that the starting material Ac-Sar10-COOH in step 1 was replaced with m-PEG8-acid (CAS 1093647-41-6). After several reaction steps, the product (AP-1) was obtained as a beige amorphous powder. The theoretical value of LC-MS (ESI, m / z) was 1384.64, and the measured value was 1385.66 (M+H).
[0275] Synthesis of reference standard MC-Val-Cit-PABC-DX8951 Following the method described in reference WO2020233174A1, Mc-Val-Cit-OH (purchased from Shanghai Haoyuan Chemical) was reacted with bis(4-nitrophenyl) carbonate to obtain an activated nitro ester, which was then further reacted with ethatecan mesylate (purchased from Shanghai Haoyuan) to obtain the reference compound MC-Val-Cit-PAB-DX8951.
[0276] [Example 2: General Method for ADC Fabrication] Antibody or antigen-binding fragments, such as Trastuzumab stock solution targeting HER2 (heavy chain sequence as shown in SEQ ID NO:3, light chain sequence as shown in SEQ ID NO:4) and / or hRS7 monoclonal antibody (Sacituzumab) targeting Trop-2, were diluted to 2 mg / mL with 50 mM potassium dihydrogen phosphate-sodium hydroxide (KH2PO4-NaOH) / 150 mM sodium chloride (NaCl) / 1 mM diethyltriaminepentaacetic acid (DTPA), pH 7 reaction buffer, and 6.0 times excess molar of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added. The reaction solution was stirred at 35°C for 2.5 hours.
[0277] The above reaction solution was cooled to 8°C, and an appropriate amount of dimethylacetamide (DMA) was added without purification. Then, 6-15 times the excess molar of the reference drug molecule or drug linker conjugate A1~A29 (10 mg / ml pre-dissolved in DMA) was added to ensure that the volume ratio of DMA in the reaction system did not exceed 20%. The mixture was stirred at 37°C for 3 hours for coupling.
[0278] The coupling reaction mixture was purified by desalting column filtration using histidine-acetic acid / sucrose gel filtration at pH 6.0, and the peak sample was collected based on the UV280 absorbance. The sample was then sterilized by filtration through a 0.15 μm pore size filter and stored at -60°C.
[0279] Preparation of antibody-drug conjugate 1 (control ADC1) Following the general method described above, a 10-fold excess of the reference standard MC-Val-Cit-PAB-DX8951 was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-conjugate 1. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 1. The proportion of polymer 1 was approximately 26%, and the proportion of polymer 2 was approximately 20%. The drug loading (DAR) was approximately 4-5, as obtained by UV analysis.
[0280] Preparation of antibody-drug conjugate 2 (control ADC2) Following the general method described above, a 12-fold excess of the reference standard Deruxtecan (purchased from Shanghai Haoyuan Chemical) was conjugated with reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 2. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 2. The proportion of polymers was approximately 2%. The drug loading (DAR) was determined by hydrophobic interaction high performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 3.
[0281] Preparation of antibody-conjugate 3 Following the general method described above, an 8-fold excess of compound (A-2) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-conjugate 3. The content of the polymers was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 4. The proportion of polymer 1 was approximately 6.8%, and the proportion of polymer 2 was approximately 7.7%. The drug loading (DAR) was approximately 6-7, as obtained by UV analysis.
[0282] Preparation of antibody conjugate 4 Following the general method described above, a 12-fold excess of compound A-4 was conjugated with reduced Trastuzumab monoclonal antibody to obtain antibody-drug conjugate 4 with a drug loading (DAR) of approximately 7-8. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 5. The proportion of polymer 1 was approximately 0.3%. The drug loading (DAR) was further analyzed by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram was shown in Figure 6.
[0283] Preparation of antibody-drug conjugate 5 Following the general method described above, a 12-fold excess of compound (A-11) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 5. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 7. The purity of the antibody-drug conjugate 5 monomer was 99.41%. The drug loading (DAR) was determined by hydrophobic interaction high performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 8.
[0284] Preparation of antibody-drug conjugate 6 Following the general method described above, a 12-fold excess of compound (A-14) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 6. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 9. The purity of the antibody-drug conjugate 6 monomer was 99.60%. The drug loading (DAR) was determined to be approximately 7-8 by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 10.
[0285] Preparation of antibody-drug conjugate 7 Following the general method described above, a 15-fold excess of compound (A-24) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 7. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 11. The purity of the antibody-drug conjugate 7 monomer was 96.36%. The drug loading (DAR) was determined to be approximately 7-8 by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 12.
[0286] Preparation of antibody-drug conjugate 8 (control ADC3) Following the general method described above, a 12-fold excess of compound AP-1 was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 8. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 13. The purity of the monomer of antibody-drug conjugate 7 was 97.92%. The drug loading (DAR) was determined by hydrophobic interaction high performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 14.
[0287] Preparation of antibody conjugate 9 Following the general method described above, a 12-fold excess of compound (A-11) was conjugated with the reduced Patritumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 9. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 15. The purity of the antibody-drug conjugate 9 monomer was 97.92%. The drug loading (DAR) was determined to be approximately 7-8 by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 16.
[0288] Preparation of antibody conjugate 10 Following the general method described above, a 12-fold excess of compound (A-11) was conjugated with the reduced H01L02 monoclonal antibody to obtain the corresponding antibody-drug conjugate 10. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 17. The purity of the antibody-drug conjugate 10 monomer was 99.10%. The drug loading (DAR) was determined to be approximately 7-8 by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 18.
[0289] Preparation of antibody conjugate 11 Following the general method described above, a 12-fold excess of compound (A-28) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 11. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 19. The purity of the antibody-drug conjugate 11 monomer was 99.59%. The drug loading (DAR) was analyzed by hydrophobic interaction high performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 20.
[0290] Preparation of antibody conjugate 12 Following the general method described above, a 12-fold excess of compound (A-29) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain the corresponding antibody-drug conjugate 12. The content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 21. The purity of the antibody-drug conjugate 12 monomer was 99.67%. The drug loading (DAR) was determined to be approximately 7-8 by hydrophobic interaction high-performance liquid chromatography (HIC-HPLC), and the analytical chromatogram is shown in Figure 22.
[0291] Preparation of antibody conjugate 13 The hRS7 monoclonal antibody solution targeting Trop-2 was dialyzed and the buffer was changed to 50 mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH2PO4-Na2HPO4) / 50 mM sodium chloride (NaCl), pH 7.0 buffer. After measuring the concentration of the monoclonal antibody in the solution, the antibody was diluted to 5 mg / mL with the above buffer. The reaction tube was placed in an ice bath to cool for 10 minutes. 2.5 moles of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP) was added, and the reaction solution was stirred overnight at 4°C. An appropriate amount of dimethylacetamide (DMA) was added to the above unpurified reaction solution, followed by 6.0 moles of excess control drug molecule or drug linker conjugate A-11 (10 mM pre-dissolved in DMA), ensuring that the volume percentage of DMA in the reaction system did not exceed 10%, and the mixture was stirred at 4°C for 2 hours for conjugation. After conjugation, 4.0 moles of cysteine (Cysteine) were added to the reaction solution to consume the excess drug linker conjugate A-11, and the reaction was quenched by stirring at 4°C for 30 minutes. The conjugation reaction mixture was purified by filtration through a desalting column using histidine-acetic acid / sodium chloride at pH 5.5, and the filtered sample was collected. One-tenth volume of activated carbon-histidine-acetic acid / sodium chloride suspension (300 mg / mL) was added to the sample, and the mixture was stirred at room temperature for 2 hours to fully absorb the free drug molecules. The sample was then sterilized by filtration through a 0.22 μm pore size filter and stored at -80°C. The polymer content was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 25. The purity of the antibody conjugate 13 monomer was 98.95%.
[0292] The concentration of the conjugated drug in the antibody-drug conjugate can be calculated by measuring the ultraviolet absorbance of the antibody-drug conjugate aqueous solution at two wavelengths, 280 nm and 370 nm, and then the following calculation is performed.
[0293] The total absorbance at any given wavelength is equal to the sum of the absorbances of all the light-absorbing chemicals in the system (absorbance additivity). Therefore, based on the assumption that the molar absorption coefficients of the antibody and drug do not change before and after antibody-drug conjugation, the antibody concentration and drug concentration in the antibody-drug conjugate are expressed by the following formula. A280=AD,280+AA,280=εD,280CD+εA,280CA (1) A370=AD,370+AA,370=εD,370CD+εA,370CA (2)
[0294] Wherein, A280 represents the absorbance of the antibody-drug conjugate solution at 280 nm, and A370 represents the absorbance of the antibody-drug conjugate solution at 370 nm. AD,280 represents the absorbance of the drug linker conjugate at 280 nm, and AD,370 represents the absorbance of the drug linker conjugate at 370 nm. AA,280 represents the absorbance of the antibody at 280 nm, and AA,370 represents the absorbance of the antibody at 370 nm. εD,280 represents the molar absorptivity of the drug linker conjugate at 280 nm, εD,370 represents the molar absorptivity of the drug linker conjugate at 370 nm, εA,280 represents the molar absorptivity of the antibody at 280 nm, and εA,370 represents the molar absorptivity of the antibody at 370 nm. CD represents the concentration of the drug linker conjugate in the antibody-drug conjugate solution, and CA represents the concentration of the antibody in the antibody-drug conjugate solution.
[0295] εA,280 can be estimated from the amino acid sequence of the antibody using known calculation methods (Protein Science, 1995, vol. 4, 2411-2423), while εA,370 is generally zero. εD,280 and εD,370 are obtained by measuring the absorbance of the drug conjugate solution at a certain molar concentration, according to the Lambert-Beer law. The values of A280 and A370 are measured using an ELISA reader or UV spectrophotometer, and the values of the above four molar absorption coefficients are substituted into the simultaneous equations (1) and (2) to calculate the values of CA and CD. The average number of drug molecules conjugated in each antibody molecule is then DAR = CD / CA. The UV absorbance coefficients of compound A-11 are εD,280 = 6480 and εD,370 = 16483, which are used to calculate the drug-antibody conjugation ratio in this example. The DAR value of antibody conjugate 13 is approximately 4.0.
[0296] Preparation of antibody conjugate 14 The hRS7 monoclonal antibody solution targeting Trop-2 was dialyzed and the buffer was changed to 50 mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH2PO4-Na2HPO4) / 50 mM sodium chloride (NaCl), pH 7.0 buffer. After measuring the concentration of the monoclonal antibody in the solution, the antibody was diluted to 5 mg / mL with the above buffer. The reaction tube was placed in an ice bath to cool for 10 minutes. 2.5 molars of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP) was added, and the reaction solution was stirred overnight at 4°C. An appropriate amount of dimethylacetamide (DMA) was added to the above unpurified reaction solution, followed by 6.0 molars of excess control drug molecule or drug linker conjugate A-14 (10 mM pre-dissolved in DMA), ensuring that the volume percentage of DMA in the reaction system did not exceed 10%, and the mixture was stirred at 4°C for 2 hours for conjugation. After conjugation, 4.0 moles of cysteine (Cysteine) were added to the reaction solution to consume the excess drug linker conjugate A-14, and the reaction was quenched by stirring at 4°C for 30 minutes. The conjugation reaction mixture was purified by filtration through a desalting column using histidine-acetic acid / sodium chloride at pH 5.5, and the filtered sample was collected. One-tenth volume of activated carbon-histidine-acetic acid / sodium chloride suspension (300 mg / mL) was added to the sample, and the mixture was stirred at room temperature for 2 hours to fully absorb the free drug molecules. The sample was then sterilized by filtration through a 0.22 μm pore size filter and stored at -80°C. The polymer content was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 26. The purity of antibody conjugate 14 monomer was 98.20%. The ultraviolet absorptivity of compound A-14 is εD,280=5932, εD,370=14997, which are used to calculate the drug-antibody conjugate ratio in this example. The DAR value of antibody conjugate 14 is approximately 4.2.
[0297] Preparation of antibody-drug conjugate 15 The hRS7 monoclonal antibody solution targeting Trop-2 was dialyzed and the buffer was changed to 50 mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH2PO4-Na2HPO4) / 50 mM sodium chloride (NaCl), pH 7.0 buffer. After measuring the concentration of the monoclonal antibody in the solution, the antibody was diluted to 5 mg / mL with the above buffer. The reaction tube was placed in an ice bath to cool for 10 minutes. 2.5 molars of tris(2-carboxyethyl)phosphonic acid hydrochloride (TCEP) was added, and the reaction solution was stirred overnight at 4°C. An appropriate amount of dimethylacetamide (DMA) was added to the above unpurified reaction solution, followed by 6.0 molars of excess control drug molecule or drug linker conjugate A-24 (10 mM pre-dissolved in DMA), ensuring that the volume percentage of DMA in the reaction system did not exceed 10%, and the mixture was stirred at 4°C for 2 hours for conjugation. After conjugation, 4.0 moles of cysteine (Cysteine) were added to the reaction solution to consume excess drug linker conjugate A-24, and the reaction was quenched by stirring at 4°C for 30 minutes. The conjugation reaction mixture was purified by filtration through a desalting column using histidine-acetic acid / sodium chloride at pH 5.5, and the filtered sample was collected. One-tenth volume of activated carbon-histidine-acetic acid / sodium chloride suspension (300 mg / mL) was added to the sample, and the mixture was stirred at room temperature for 2 hours to fully absorb the free drug molecules. The sample was then sterilized by filtration through a 0.22 μm pore size filter and stored at -80°C. The polymer content was analyzed by size exclusion chromatography (SEC-HPLC), and the analytical chromatogram is shown in Figure 27. The purity of antibody conjugate 15 monomer was 96.36%. The ultraviolet absorptivity of compound A-24 is εD,280=4723 and εD,370=12467, which are used to calculate the drug-antibody conjugate ratio in this example. The DAR value of antibody conjugate 15 is approximately 4.0.
[0298] The disclosed compound and its prepared ADC showed higher monomer purity at higher drug loading compared to the control ADC, suggesting better stability. Furthermore, hydrophobic interaction high-performance liquid chromatography (HIC-HPLC) analysis revealed that the disclosed ADC had a lower retention time than the control molecule, more closely resembling the naked antibody, indicating better hydrophilicity and potentially a longer half-life and stronger in vivo efficacy.
[0299] [Example 3: Antibody Conjugate Stability Test] Antibody-addictive drugs (ADCs) based on camptothecin-based topoisomerase inhibitors, such as Sacituzumab govitecan (Trodelvy) and Trastuzumab Deruxtecan (Enhertu), typically exhibit high drug-to-antibody loading ratios (DARs). However, due to the aromatic fused-ring structure of camptothecin molecules, they possess strong hydrophobicity, inevitably affecting the stability of these ADC molecules. The ADC prepared in this invention incorporates a polyinosinic acid peptide chain at a specific position, exhibiting a better "barrier effect" and potentially better stability. We designed an accelerated antibody stability assay to verify this hypothesis.
[0300] The molecules being compared include: 1. Trastuzumab 2. Antibody-conjugate 2 3. Antibody-conjugate 5 4. Antibody-conjugate 6 5. Antibody-conjugate 7 5. Antibody-conjugate 8
[0301] We diluted the analyte samples to a concentration of 5 mg / mL with formulation buffer (20 mM Histidine-acetic acid, 150 mM NaCl, pH 5.5), and then used 50 μL for direct testing or incubated in a 55°C water bath for 1 h, 2 h, 5 h, 24 h, 48 h, and 72 h before testing (accelerated stability test). The concentration changes of the samples were detected by UV chromatography, and the contents of normal-structure ADC molecules (main peak) and polymer molecules in the samples were quantitatively analyzed using a TSK-GEL SWXL3000 size exclusion column on an Agilent 1260 Infinity II bioinert liquid chromatography system.
[0302] The HPLC mobile phase was 200 mM phosphate buffer (pH 7.0) + 150 mM KCl + 15% IPA, the column temperature was 25 °C, the injection volume was 7 μL, the flow rate was 0.75 mL / min, and the UV detection wavelengths were 280 nm and 370 nm.
[0303] The statistical results of sample concentration changes are shown in Figure 23. We found that trastuzumab and its corresponding antibody-drug conjugates 5 and 6 have good thermal stability, and the concentration changes are small during the 0-72 hours. However, the samples of antibody-drug conjugates 2, 7 and 8 showed a rapid decrease in ADC concentration and precipitation after 24 hours, which led to a rapid decrease in sample concentration.
[0304] Further analysis of the changes in the proportion of polymerized molecules in the above accelerated stability test samples using size exclusion chromatography was conducted. The statistical results are shown in Figure 24. Consistent with the trend of sample concentration changes, the sample stability was ranked from highest to lowest as follows: trastuzumab Antibody-conjugate 5 > Antibody-conjugate 6 > Antibody-conjugate 7 > Antibody-conjugate 8 Antibody conjugate 2.
[0305] The above results verify that the hydrophilic polyinosinic peptide chain at a specific position in this invention has a "barrier effect" that brings an "unexpected" improvement in the stability of antibody-drug conjugate molecules.
[0306] [Example 4: In vitro cytotoxic activity test] Human lung squamous cell carcinoma cells NCI-H2170 and LK-2, and human breast cancer cells MDA-MB-231 were selected as cell lines for in vitro activity assays in this experiment. The expression level of TROP2 antigen on the surface of these human tumor cells was measured by flow cytometry (FACS) (expressed as rMFI). Simultaneously, the dose-response effects of antibody-drug conjugate 13, DS-1062a (control drug, prepared according to the method described in US11173213B2), hIgG-deruxtecan conjugate, and hIgG-A-11 conjugate on cell killing were observed. The final concentration of the antibody-drug conjugates was set at 500 nM as the initial concentration, and nine series of concentrations (5-fold serial dilutions) were designed from 500 to 0.1 nM. Changes in cell killing (or inhibition) were observed after 120 hours. Chemiluminescent staining (Luminescent Cell Viability Assay) was performed, and the IC50 was calculated after reading the fluorescence data.
[0307] As shown in Table 1, both antibody conjugate 13 and DS-1062a (control drug) can significantly inhibit tumor cell proliferation, which is significantly stronger than negative-to-positive drugs IgG-deruxtecan conjugate and IgG A-1 conjugate. The antibody conjugate 13 of the present invention is significantly superior to the clinical drug DS-1062a.
[0308] Table 1
[0309] Based on the above activity test results, the ADCs prepared from the compounds disclosed herein all exhibit good in vitro antitumor activity, especially against tumor cells with low expression of relevant antigens, where the antibody-drug conjugates disclosed herein show more significant advantages.
[0310] [Example 5: In vivo antitumor efficacy assay] The efficacy of the combination of the invention can be measured in vivo, i.e., by implanting allogeneic or xenografts of cancer cells into rodents and treating tumors with the combination. Test mice are treated with the drug or controls and monitored for weeks or longer to measure time to tumor doubling, logarithmic cell killing, and tumor suppression.
[0311] In vivo anti-tumor experiment Human lung squamous cell carcinoma cell line NCI-H2170 (ATCC) was suspended in physiological saline, and 4 × 10⁷ cells were subcutaneously transplanted into the right lateral aspect of female nude mice. On day 6, mice were randomly assigned to groups. Day 0 was designated as the grouping day. On day 0, antibody-drug conjugate 13 (positive control), DS-1062a (positive control), and hIgG-A-11 conjugate (negative control) were administered intravenously via the tail vein at a dose of 5 mg / kg.
[0312] The results are shown in Figure 28. For human lung squamous cell carcinoma NCI-H2170, both DS-1062a and antibody-drug conjugate 13 showed antitumor activity at a single dose of 5 mg / kg. At a single dose of 5 mg / kg, the antitumor activity of antibody-drug conjugate 13 was significantly stronger than that of the control drug DS-1062a. Furthermore, the trend of mouse body weight change (Figure 29) suggests that antibody-drug conjugate 13 has good safety.
[0313] The activity test results showed that the ADCs prepared from the disclosed compounds all exhibited certain in vivo antitumor activity, demonstrating significantly stronger antitumor activity compared to the control samples. Tumor-bearing mice tolerated all the drugs well, without experiencing symptoms such as weight loss.
[0314] The foregoing detailed description is provided by way of explanation and illustration and is not intended to limit the scope of the appended claims. Various variations of the embodiments described herein will be apparent to those skilled in the art and are reserved for use within the scope of the appended claims and their equivalents.
[0315] <110> Shanghai Huilian Bio-Pharm Co., Ltd., a mainland Chinese company <120> Preparation methods and applications of antibody-drug conjugates <130> 0223-PA-004TW <160> 12 <170> PatentIn version 3.5 <210> 1 <211> 451 <212> PRT <213> Artificial Sequence <220> <223> Sacituzumab heavy chain <400> 1 <210> 2 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Sacituzumab light chain <400> 2 <210> 3 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Trastuzumab heavy chain <400> 3 <210> 4 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Trastuzumab light chain <400> 4 <210> 5 <211> 448 <212> PRT <213> Artificial Sequence <220> <223> Pertuzumab heavy chain <400> 5 <210> 6 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Pertuzumab light chain <400> 6 <210> 7 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Enfortumab heavy chain <400> 7 <210> 8 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Enfortumab light chain <400> 8 <210> 9 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Patritumab heavy chain <400> 9 <210> 10 <211> 220 <212> PRT <213> Artificial Sequence <220> <223> Patritumab light chain <400> 10 <210> 11 <211> 451 <212> PRT <213> Artificial Sequence <220> <223> H01L02 Heavy Chain <400> 11 <210> 12 <211> 213 <212> PRT <213> Artificial Sequence <220> <223> H01L02 Light Chain <400> 12
Claims
1. A compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure shown in formula (C-Trop-2): (C-Trop-2) where Q1 is a linker coupled with a thiol group, L1 is -L1a-C(=O)-, and L1a is selected from the group consisting of C1-C12 alkylene groups and arylene groups that are substituted as desired; L2 is a polypeptide residue selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamate-valine-alanine (Glu-Val-Ala), glutamate-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-aspartate (Ala-Ala-Asn), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly); L3 is a structure selected from the group consisting of substituted, and substituted, In L3, the benzene ring is connected to the substituted polyinosine residue via a structural unit -X-, wherein the structural unit -X- is or, wherein X1 is selected from the group consisting of C1-C8 alkyl, wherein the substituted polyinosine residue is, n2 is 10, R is a structure selected from the group consisting of C1-C6 alkyl, C1-C6 cycloalkyl and C1-C6 alkoxy; T is a pharmaceutical unit; Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
2. The compound as claimed in claim 1, or its tautomers, meso compounds, racemates, enantiomers, diastereomers, mixtures thereof, or pharmaceutically acceptable salts thereof, wherein, Q1 is a structure selected from the following groups: , , and.
3. The compound as claimed in claim 1, or its tautomers, meso compounds, racemates, enantiomers, diastereomers, mixtures thereof, or pharmaceutically acceptable salts thereof, wherein, L1a is a C1-C7 alkylene group that is substituted as needed.
4. The compound as claimed in claim 1, or its tautomers, meso compounds, racemates, enantiomers, diastereomers, mixtures thereof, or pharmaceutically acceptable salts thereof, wherein, The structural unit -X- is, and the substituted polyinosine residue is, where n2 is 10 and R is a C1-C6 alkyl group.
5. The compound as claimed in claim 1, or its tautomers, meso compounds, racemates, enantiomers, diastereomers, mixtures thereof, or pharmaceutically acceptable salts thereof, wherein, T contains compounds with antitumor activity.
6. The compound as claimed in claim 1, or a tautomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein, T is a structure selected from the following groups: , and .
7. The compound as claimed in claim 1, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof.
8. The compound as claimed in claim 7, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab′, Fv fragment, F(ab')2, F(ab)2, scFv, di-scFv, VHH, and dAb.
9. The compound as claimed in claim 1, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the Ab is hRS7.
10. The compound as claimed in claim 1, or a tautomer, meso compound, racemic mixture, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein, The compound contains structures selected from the group consisting of (C-Trop-2-3), (C-Trop-2-4), (C-Trop-2-5), (C-Trop-2-6), and (C-Trop-2-8), where Ab is a ligand capable of binding Trop-2 and m is a number from 1 to 8.
11. A compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein, The compound contains structures selected from the group consisting of (C-Trop-2-3), (C-Trop-2-4), (C-Trop-2-5), (C-Trop-2-6), and (C-Trop-2-8), where Ab is a ligand capable of binding Trop-2 and m is a number from 1 to 8.
12. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 11, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, and, where appropriate, a pharmaceutically acceptable carrier.
13. Use of a compound comprising any one of claims 1 to 11, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 12, in the preparation of a medicament for the treatment and / or prevention of tumors.
Citation Information
Patent Citations
Antibody drug conjugates having linkers comprising hydrophilic groups
WO2020236841A2
